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Unknown primary head and neck squamous cell carcinoma is a rare condition with 
poor prognosis compared to tumours with a known primary site.  There are no consistent 
guidelines or strong evidence to guide the management of these tumours.  Surgery or 
radiotherapy are equally common primary treatment modalities for these patients.  A 
systematic review was therefore conducted to assess the effectiveness of primary surgery 
compared to primary radiotherapy. 
A pre-defined search strategy was used to search PubMed, Embase and ProQuest 
databases.  Titles and abstracts were screened against inclusion criteria and full texts of 
potentially relevant studies retrieved to assess final eligibility.  These studies underwent 
critical appraisal by two independent reviewers for assessment of their methodological 
quality.  Five of these studies were included in pooled meta-analysis.  Primary outcome 
measures of interest were overall survival and regional and relapse free survival.  Primary 
emergence, neck recurrence and distant metastasis rates were extracted and analysed to 
substantiate the primary outcome measures. 
Following screening of 9376 unique records identified by the search, ten 
retrospective cohort studies, including a total of 655 participants that analysed data from 
patient registries, were included in the review.  Across the included studies, quality of 
data synthesis and reporting was poor, especially the stratification of end point survival 
data, summary statistics, reporting of treatment related toxicities and quality of life 
measures.  Meta-analysis (n=5) revealed no statistically significant difference in overall 
survival based on the primary treatment modality (HR:0.86, p=0.60) but favoured primary 
surgery for regional and relapse free survival (HR:0.57, p=0.07).    Early stage disease at 
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the time of treatment initiation had improved overall survival, regardless of the treatment 
modality (HR:0.27, p=0.008).  Rate of primary emergence (median = 5%) after five years 
did not increase when the mucosa was not irradiated in suspected cutaneous cancer 
patients.  However, treatment with neck dissection alone without patient risk stratification 
increased primary emergence rates as well as neck failure rates. 
In conclusion, there is no treatment modality dependent difference in overall 
survival or regional and relapse free survival.  Cutaneous origin of unknown primary head 
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1 CHAPTER 1: INTRODUCTION 
1.1 Review question 
What is the effectiveness of primary surgery compared to primary radiotherapy in 
the treatment of unknown primary head and neck squamous cell carcinoma? 
1.2 Significance of the research question 
Head and neck squamous cell carcinoma (HNSCC) of unknown primary site 
(HNCUP) is described as the presence of cervical lymph node metastasis without an 
identifiable primary tumour site.1 A truly unknown primary HNSCC is relatively rare, 
accounting for approximately 3% of newly diagnosed HNSCC.2  In the absence of 
advanced imaging techniques such as fluorodeoxyglucose positron emission tomography 
(FDG-PET) currently available for detection of small tumours hidden from plain site, 
confirmed rates are historically as high as 10%.3  In HNCUP, the primary tumour is 
thought to arise from the upper aero-digestive tract or the skin, based on the patterns of 
lymphatic drainage mapped in previous studies.4 Treatment paradigms for HNCUP are 
heterogeneous; treatment options include a primary neck dissection with adjuvant 
radiotherapy or primary radiotherapy with concurrent chemotherapy.  Recently, however, 
diagnostic transoral robotic surgery (TORS) assisted endoscopic procedures have begun 
to be adopted as a component of primary surgical treatment.  The advantages of the TORS 
tongue base mucosectomy include exclusion of one possible site for an occult primary 
lesion, eliminating the need to irradiate the tongue base.5  The non-surgical approach to 
HNCUP includes primary radiotherapy to the neck nodal site and suspected mucosal sites, 
with or without chemotherapy.6  A planned neck dissection (PND) may also be included 
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in the treatment protocol following chemoradiation,7 although controversy exists 
regarding the role of a PND, as no clear survival benefit has been shown after primary 
chemoradiation, except as a salvage procedure following treatment failure.8 
The objective of the systematic review presented in this thesis is to assess the 
effectiveness of common treatment modalities for HNCUP.  Mainstream modalities are 
primary surgery, followed by adjuvant radiotherapy, with or without the addition of 
chemotherapy, or primary radiation with chemotherapy.  An existing meta-analysis by Liu 
et al.9 that evaluated the optimum radiotherapy options for HNCUP included multiple 
comparisons: surgical versus radiotherapy, unilateral versus bilateral neck irradiation and 
neck only versus neck and possible primary site irradiation.  They found that surgery 
followed by adjuvant radiotherapy had a five-year overall survival advantage (RR = 0.74, 
95% CI 0.59 – 0.92, p < 0.001).  However, the usefulness of this analysis to elucidate 
which treatment modality is superior and better inform clinical practice is questionable 
due to the inclusion of various radiation techniques that are no longer used in HNCUP in 
the pooled analysis and the inclusion studies without direct comparison to other treatment 
modalities.  Another comprehensive outcomes review of HNCUP, appraising studies from 
1998 to 2010, reported no statistically significant five-year survival difference between 
primary surgery and primary radiotherapy.10  The authors also reported a neck stage 
dependent reduction in overall survival where smaller neck nodes had improved 
survival.10 However, in this study, the analysis was not stratified based on type of 
radiotherapy used nor morbidity associated with the treatment.   
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1.3 Epidemiology of head and neck squamous cell carcinoma 
Squamous cell carcinoma (SCC) is the predominant histopathological diagnosis of 
head and neck cancers.11 It is the sixth most common cancer worldwide, with an incidence 
of up to 600,000 cases per year with a predilection to the male gender.12  Prior to the 
2000s, tobacco and alcohol use were the predominant identifiable causative agents for 
HNSCC.13  However, in recent times, the human papilloma virus (HPV) has been 
identified to play a more dominant role as a causative agent.14 Interestingly, HPV positive 
cancers are affecting younger patients of higher socio-economic status compared to the 
patients with HPV negative HNSCCs with no clear reasons identified to date.15 
1.4 Mucosal, cutaneous and lymphatic anatomy of the head and neck region 
Lymph nodes in the head and neck region are divided into multiple segments (also 
known as lymph node levels), based on generally consistent anatomical landmarks and 
consistent with biologically significant pathways of regional tumour metastasis (Figure 
1).16  This classification is used to describe various forms of lymph node dissections in 
head and neck surgery.  Classically, regions of the neck are divided into cervical triangles 
based on prominent musculature, namely, anterior, carotid and posterior triangles.  Each 
of these compartments can be further divided.  The anterior triangle is subdivided into the 
submandibular and submental triangles by the anterior belly of the digastric muscle.  The 
carotid triangle is subdivided into superior and inferior triangles by the superior belly of 
the omohyoid muscle.  The posterior triangle is further divided into occipital and 




Figure 1.  Neck lymph node levels, as described by the American Joint Committee on Cancer, 
showing relevant anatomical landmarks and a schematic view of described nodal levels.  Image 
courtesy of A.Prof Frank Gaillard, Radiopaedia.org, rID: 9618, creative commons license.18 
 
Classification of neck lymph nodes have evolved since the first anatomical 
description by Henri Rouviere in 1938.19  It has been revised by Shah et al. in 1981,20,Som 
et al. in 200021,22  and most recently by the American Academy of Otolaryngology–Head 
and Neck Surgery (AAOHNS).23  The improvement in the classification system has been 
driven by the clinical applicability and ability for radiological discrimination of node 
levels.  In the most recent iteration, neck lymph nodes are divided into six main levels 
and six sublevels (Table 1, Figure 1).  The boundary separating level 1b from 2a is 
formally defined as the border of the stylohyoid muscle; however, the stylohyoid muscle 




Table 1. Surgically distinct lymph node areas divided into “levels” with specific 
anatomical boundaries 
Lymph node level Anatomical boundaries 
Level 1a Mandibular symphysis 
Anterior belly of contralateral and ipsilateral digastric muscle 
Body of hyoid bone 
Level 1b Body of mandible 
Anterior belly of digastric muscle 
Stylohyoid muscle 
Body of hyoid bone 
Level 2a Skull base 
Inferior border of the hyoid bone 
Stylohyoid muscle 
Spinal accessory nerve 
Level 2b Skull base 
Horizontal plane defined by the inferior border of the hyoid bone 
Spinal accessory nerve 
Lateral border of sternocleidomastoid muscle 
Level 3 Horizontal plane defined by the inferior border of the hyoid bone 
Horizontal plane defined by the inferior border of the cricoid cartilage 
Lateral border of the sternohyoid muscle 
Lateral border of the sternocleidomastoid muscle 
Level 4 Inferior border of the cricoid cartilage 
Clavicle 
Lateral border of the sternohyoid muscle 
Lateral border of the sternocleidomastoid muscle 
Level 5a Apex of the sternocleidomastoid and trapezius muscle 
Horizontal plane defined by the inferior border of cricoid cartilage 
Lateral border of the sternocleidomastoid muscle 
Medial border of the trapezius muscle 
Level 5b Horizontal plane defined by the inferior border of the cricoid cartilage 
Clavicle 
Lateral border of the sternocleidomastoid muscle 
Medial border of the trapezius muscle 
Level 6 Hyoid bone 
Suprasternal notch 
Common carotid artery either side 
 
All mucosal sites of the head and neck region could be a potential target for an 
occult tumour.  These sites can be separated to nasal cavity (including paranasal sinuses), 
oral cavity, nasopharynx, oropharynx, laryngopharynx (or hypopharynx) and the larynx.25  
However, the nasopharynx, oropharynx and hypopharynx is considered the most at risk 
for occult primary tumours giving rise to an HNCUP.  In countries such as Australia, 
where smoking rates are significantly lower, the rates of hypopharyngeal cancers have 




Regular exposure to ultraviolet light from the sun increases the incidence of 
cutaneous SCC in countries such as Australia.26  Head and neck cutaneous sites are 
especially at risk.  These cancers could also present as a HNCUP.  Head and neck 
cutaneous sites at risk include skin covering the scalp, face, ears and neck.  Cutaneous 
SCC from a head and neck source has a regional metastatic rate of approximately 5%27 
and metastasis to intra-parotid lymph nodes is also common in contrast to mucosal SCC.28  
The parotid gland is the largest salivary gland in the head and neck region, present 
bilaterally, antero-inferior to the external auditory canal, lateral to the ramus of mandible, 
and overlying the masseteric muscle.  It is closely associated to facial skin, only separated 
by the superficial musculo-aponeurotic system and the parotid fascia that overlies this 
gland, that may also allow direct invasion of cutaneous malignancies.  This salivary gland 
is unique, with intra-glandular lymph nodes due to embryologically late development of 
its capsule following the development of the surrounding lymphatic pathways.29  These 
lymph nodes located within the parotid gland are often the first-echelon nodes draining 
the skin covering the face and scalp.30  Therefore, in patients prone to cutaneous SCC 
presenting with a HNCUP, involvement of the ipsilateral parotid gland should be 
considered and included in the treatment decision, even in the absence of gross parotid 
disease. 
1.5 Pathophysiology of head and neck squamous cell carcinoma 
HNSCC arise as a result of clonal transformation of pre-cancerous lesions, 
progressing from dysplasia to carcinoma in situ and subsequently to an invasive tumour.  
Risk factors mentioned earlier lead to molecular insults that accumulate in order to 
facilitate the development of these highly aggressive malignancies.  Various molecular 
pathways are described in current literature and these are reviewed in this section. 
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1.5.1 Molecular basis of squamous cell carcinomas 
HNSCCs occur due to a combination of molecular events, including numerous gene 
mutations.  Numerous genes have been implicated in the pathogenesis of HNSCCs; these 
include NOTCH1, NOTCH2, NOTCH3, IRF6, TP53, CDKN2A, HRAS, PTEN, SYNE1, 
SYNE2, RIMS2, PCLO, Rb/INK4/ARF and PIK3CA.31  The TP53 (p53) gene pathway is 
the most common mutation identified in more than half of all HNSCC.32  p53 is a tumour 
suppressor gene that is identified in malignant as well as pre-malignant lesions such as 
leukoplakia.33  This has led to the “patch-field” progression theory of HNSCC, where a 
field of genetically abnormal mucosal tissue gaining growth advantage and further 
mutations lead to a carcinoma.34  Further research suggests that p53 mutations in adjacent 
tissue can be different from the primary neoplasm, indicating the potential for 
metachronous tumours in the same patient after accumulation of further mutations in 
adjacent tissues.35  There is also an independent association with poor survival in patients 
with a truncating or function disrupting p53 mutation compared to patients without.36 
Another key tumour suppressor gene pathway of importance is Rb/INK4/ARF.34  
Inactivation of CDKN2A via the retinoblastoma (Rb) pathway is found in up to 30% of 
tumours.37  CDKN2A under normal physiological conditions encode for cell cycle 
regulators.  These regulators include p16/INK4A and p14/ARF/INK4B.  The p16/INK4A 
pathway is particularly important in HPV positive HNSCC that is further explored in 
Section 1.5.2. 
NOTCH is an evolutionarily highly conserved signalling pathway that is also 
implicated in HNSCC differentiation.38  In benign tissue, TP63 (p63) and NOTCH1 
controls the squamous morphogenesis of mucosa.39  The transcription factor p63 is 
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expressed in keratinocytes of the basal layer and maintains their potential for proliferation, 
and the expression of NOTCH1 causes terminal differentiation into spinous and granular 
layers of the mucosa.  Loss of NOTCH1 and mutated expression of p63 remove further 
barriers to neoplastic proliferation and survival of malignant cells.39 
PI3K pathway is negatively regulated by PTEN and positively regulated by PIK3CA.  
Up to 40% of HNSCC has a PTEN mutation, causing the activation of the PI3K signalling 
pathway.  This is important in HPV positive HNSCCs as the combination of HPV E6 and 
E7 proteins with PIK3CA can lead to more invasive oropharyngeal carcinomas.40  The 
loss of p53, CDKN2A, TGFBR2/SMAD4 and amplification of CCND1 promotes 
progression and stops apoptosis of neoplasms.34  Invasive features of HNSCC are 
promoted by the loss of cell adhesion molecules such as FAT1, SMAD3 and TFGB1.34  
This summary of genetics in HNSCC implicates various molecular steps of cell 
differentiation, tumour genesis, tumour progression and tumour suppression, giving rise 
to a largely heterogeneous group of neoplasms despite a common and contiguous 
anatomical location. 
1.5.2 Role of human papilloma virus 
Human papilloma viruses are DNA viruses with more than 100 subtypes identified 
in humans.41  They are known to infect mucosal and cutaneous sites causing benign and 
malignant lesions.  High risk HPV genotypes have demonstrated a strong causal 
relationship to SCC.42  The oncogenic potential of HPV is due to viral oncogenes E6 and 
E7, blocking the function of p53 and Rb, respectively (p53 and Rb are tumour suppressor 
genes; see Section 1.5.1).43    The HPV subtypes 16 and 18 are considered high risk for 
malignant potential.  These are associated with up to 30% of head and neck cancers.44 
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However, a positive HPV status in oropharyngeal HNSCC gives an independent 
prognostic advantage compared to HPV negative mucosal carcinomas.45  HPV status may 
also determine the treatment response, as HPV positive patients are more responsive to 
radiotherapy compared to HPV negative patients.42  A recent prospective trial have 
identified a clear therapeutic response and a survival advantage for HPV positive 
oropharyngeal HNSCC patients.46  In some treatment centres, an HPV positive tumour 
neck node is considered an occult mucosal primary tumour likely originating from the 
oropharynx.47  However, up to 30% of cutaneous SCC are also p16 positive without the 
survival advantage described in mucosal primaries.48,49  A recent review and meta-
analysis confirms the presence of high-risk HPV in cutaneous SCCs more so compared 
to normal skin, although, no causative or prognostic relationship was inferred.50  
Therefore, cutaneous primary sites for HNCUP must also be considered when a neck node 
is positive for HPV.  There is no clear evidence to indicate if the survival advantage 
demonstrated in patients with known primary sites can be extrapolated to HNCUP.47   
To compound the issue, the way in which HPV is detected varies according to 
resource availability and there is no international standard for this.  p16 is a surrogate 
marker that is commonly reported in the literature and p16 protein expression can be 
detected in aspirated biopsy (through generation of a cell block) and resected samples 
using cytological techniques and immunohistochemistry, respectively.51  A positive p16 
stain provides indirect evidence of transcriptionally active HPV.52  A recent systematic 
review exploring this topic indicated that p16 expression is better at predicting HPV 
presence when more than 70% of tumour cells are stained positive.53  However, the 
percentage quantification of staining is subjective.  Direct evidence of HPV infection 
(HPV DNA) can also be detected via polymerase chain reaction (PCR) or in-situ 
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hybridization techniques.51  While the specificity of HPV hybridization is reported to be 
high, the sensitivity is low.54  Studies using a combined approach to detect HPV have 
positive patients, intermediate benefits for HPV negative but p16 positive patients, and 
limited benefits for patients with p16 negative with or without HPV positivity.55  Recently, 
the College of American Pathologists recommended the first-line use of p16 as an 
immunohistochemical marker and only to use the HPV DNA testing on a case by case 
basis for extra information or in ambiguous cases.56  The recommendation to use HPV 
DNA testing is largely based on access to technology and associated cost.  The American 
Joint Committee on Cancer (AJCC) recommends a combined approach for reporting HPV 
status.57  Prior to the availability of HPV testing, tumour morphology was used to 
differentiate tumour prognosis and the Basaloid histological variant is often associated 
with HPV positivity.  Recent research however, suggests a poor congruence between 
histological types and HPV positivity and does not recommend this as a primary method 
of inferring HPV positivity.58 
1.6 Classification of head and neck squamous cell carcinoma 
Appropriate clinical and pathological staging of cancer is crucial for clinical 
decision making.  Staging involves the grouping of patients based on similarities 
concerning anatomy and other relevant factors.  This categorisation becomes useful for 
future research and standardised survival analysis to predict best practise for patients.  
The AJCC regularly reviews staging systems to appropriately revise the staging based on 
current evidence.  Until 2017, HNSCC was staged using the seventh edition of AJCC 
staging manual.59  Staging of HNSCC is currently based on the International Union 
Against Cancer (UICC) TNM (tumour, nodes and metastasis) classification of malignant 
tumours, and the 8th Edition or the AJCC staging manual.57  The eighth edition was 
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released in mid-2016 for utilisation from 1 January 2017.  Both systems identified T-
category based on local tumour growth, N-category (Table 2) based on regional nodal 
spread of tumour and M-category based on distant metastasis, beyond the head and neck 
region.  Combination of the TNM categories allows for an overall four-tier overall staging 
system, with stages 1-2 considered early and stages 3-4 considered advanced stage 
malignancy with minor adjustments based on viral mediated of malignancy (Tables 3, 4 
and 5).57  This tiered organisation of staging allows for treatment decision making 
processes to choose between curative verses palliative, and single-modality versus multi-
modality treatment regimens. The most important change from the 7th to the 8th edition 
of AJCC TNM staging system is the inclusion of prognostic advantage of HPV positive 
malignancies and the prognostic disadvantage of extra nodal extension of tumour.57,60  
The clinical component of staging relies on physical examination of the patient with the 
aid of radiological findings (Table 6), while pathological staging is based on the analysis 
of the histopathological specimen after surgical resection of the tumour (Table 3).  At 
present, p16 status is based on tissue immunohistochemistry from an initial biopsy of the 
suspected tumour or following surgical resection of the neoplasm. 
Table 2.  HNCUP pathological staging of lymph nodes AJCC/UICC 201760 
Node category Pathological criteria 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 
Metastasis in a single ipsilateral lymph node 
3cm or smaller in greatest dimension 
No extra-nodal extension 
N2  
N2a 
Metastasis in a single ipsilateral node 
3cm or smaller 
With extra-nodal extension 
OR 
Metastasis in a single ipsilateral lymph node 
Larger than 3cm but smaller than 6cm 
No extra-nodal extension 
N2b 
Metastasis in multiple ipsilateral lymph nodes 
All smaller than 6cm 
No extra-nodal extension 
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Node category Pathological criteria 
N2c 
Metastasis in bilateral or contralateral lymph nodes 
All smaller than 6cm 
No extra-nodal extension 
N3  
N3a Metastasis in a lymph node larger than 6cm No extra-nodal extension 
N3b 
Metastasis in a single ipsilateral lymph node larger than 3cm 
With extra-nodal extension 
OR 
Multiple ipsilateral, contralateral, or bilateral nodes of any size 
With extra-nodal extension 
OR 
A single contralateral node smaller than 3cm 
With extra-nodal extension 
HNCUP – head and neck carcinoma of unknown primary site, AJCC – American Joint Committee on Cancer, UICC 
– International Union Against Cancer, N – neck 
Table 3. Non-virally mediated HNCUP prognostic staging AJCC/UICC 201760 
T – stage N – stage M – stage Overall  stage 
T0 N1 M0 III 
T0 N2 M0 IV-A 
T0 N3 M0 IV-B 
T0 N – Any M1 IV-C 
HNCUP – head and neck carcinoma of unknown primary site, AJCC – American Joint Committee on Cancer, UICC 
– International Union Against Cancer, N – neck 
Table 4. EBV mediated HNCUP prognostic staging AJCC/UICC 201760 
T – stage N – stage M – stage Overall stage 
T0 N1 M0 II 
T0 N2 M0 III 
T0 N3 M0 IV-A 
T0 N – Any M1 IV-B 
EBV – Epstein Barr virus, HNCUP – head and neck carcinoma of unknown primary site, AJCC – American Joint 
Committee on Cancer, UICC – International Union Against Cancer, T – primary tumour, N – neck, M – distant 
metastasis, EBV – Epstein Barr virus 
Table 5. Human papilloma virus (HPV) mediated HNCUP prognostic staging AJCC/UICC 
201760 
T – stage N – stage M – stage Overall stage 
T0 N1 M0 I 
T0 N2 M0 II 
T0 N3 M0 III 
T0 N – Any M1 IV 
HPV – human papilloma virus, HNCUP – head and neck carcinoma of unknown primary, AJCC – American Joint 
Committee on Cancer, UICC – International Union Against Cancer, T – primary tumour, N – neck, M – distant 
metastasis, HPV – human papilloma virus 
Table 6. HNCUP clinical staging of lymph nodes AJCC/UICC 201760 
Node Category Clinical criteria 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single ipsilateral lymph node 
13 
 
Node Category Clinical criteria 
3cm or smaller in greatest dimension 
No extra-nodal extension 
N2  
N2a 
Metastasis in a single ipsilateral lymph node 
Larger than 3cm but smaller than 6cm 
No extra-nodal extension 
N2b 
Metastasis in multiple ipsilateral lymph nodes 
All smaller than 6cm 
No extra-nodal extension 
N2c 
Metastasis in bilateral or contralateral lymph nodes 
All smaller than 6cm 
No extra-nodal extension 
N3  
N3a Metastasis in a lymph node larger than 6cm No extra-nodal extension 
N3b Metastasis in any lymph node with clinically overt extra-nodal extension or invasion of skin overlying the lymph node 
HNCUP – head and neck carcinoma of unknown primary, AJCC – American Joint Committee on Cancer, UICC – 
International Union Against Cancer, N – neck 
1.7 Current diagnostic modalities for identification of unknown primary head and 
neck carcinoma 
In current practice, the diagnostic approach to locating the primary site includes 
clinical examination including flexible nasendoscopic examination, radiological studies, 
rigid endoscopic biopsies and biomarker identification of fine needle aspirates or core 
biopsies of the cervical nodal disease.61  Radiologically, whole body positron emission 
tomography (PET) scans,62 high resolution contrast-enhanced computed tomography 
(CT) and magnetic resonance imaging (MRI) are all commonly utilised.63  Surgically, 
unilateral or bilateral tonsillectomies,64 targeted biopsies of the tongue base and more 
recently mucosectomy by either TORS5,65 or other means can be used.  Surrogate and 
direct biomarkers of causative agents such as HPV and the Epstein Barr virus (EBV) can 
also be utilised for identifying a possible primary site.66  Whilst a broad range of 
modalities are described above, the approach chosen is largely dependent on the local 
availability of resources and clinical expertise.  Due to the lack of high level evidence, 
some modalities are overlooked and others over-represented.67  A recent study by Dale et 
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al.67 highlighted the poor diagnostic value of over-utilised modalities in the identification 
of the primary site, with PET scanning only having a detection rate of 7%.  Hatten et al. 
reported an 80% primary site detection rate using TORS-assisted endoscopy procedures.5  
While the difference in point estimate (7% detection rate compared to 80%) between these 
studies appears to be very large, the lack of studies with direct comparison and widely 
distributed baseline characteristics does not allow for ready or valid comparison of 
published data. 
1.8 Current treatment modalities for unknown primary head and neck carcinoma 
Surgical and non-surgical treatment options are described for the management of 
HNCUP.68  However, the choice of optimum treatment modality remains controversial. 
1.8.1 Surgical options 
Comprehensive dissection of lymph nodes from the affected side of the neck is the 
current surgical option for HNCUP.  The type or extent of neck dissection is modified 
based on the involved nodal levels and invasion into adjacent structures.  The need for 
adjuvant radiotherapy following neck dissection is mandatory in HNCUP due to poor 
survival without adjuvant radiotherapy.68,69  Comprehensive lymph node dissection to 
treat HNCUP as a primary modality has shown improved locoregional control and 
survival benefit.68,70 
Lymph node dissection is based on the levels described earlier (Section 1.4, Table 
1, Figure 1) and can be in the form of a modified radical neck dissection (MRND) or a 
selective neck dissection (SND).  The comprehensive clearance of lymph nodes from a 
complete ipsilateral compartment of the neck (level 1 to level 5), with some disease 
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dependent and practitioner dependent variability, is termed a MRND.  In this surgical 
procedure, the lymph nodes in described level 1, 2, 3, 4 and 5 are dissected out while 
frequently preserving the sternocleidomastoid muscle, internal jugular vein and spinal 
accessory nerve.  SND refers to a neck dissection where the affected and surrounding 
nodal levels are dissected without comprehensively dissecting all ipsilateral neck lymph 
node levels.  For example, a SND would include levels 2 to 4, provided the malignant 
node is not in level 1 or 5 of the ipsilateral neck.  There are no randomised datasets to 
definitively inform the best type of neck dissection to conduct for an HNCUP.  However, 
a recent study has found that SND including levels 2 to 4 should be considered in patients 
with no clinical or radiological evidence of nodal involvement in levels 1 or 5 of the 
ipsilateral neck.  This recommendation was based on a small study (n=25) with a median 
follow-up of 33 months, where occult disease in levels 1 and 5 following MRND was 0% 
and 6%, respectively.71 
Tonsillectomy is considered a standard component of the contemporary diagnostic 
process for a HNCUP,2 nonetheless, this is a surgical procedure and forms part of the 
overall surgical-interventions for these patients.  Various tonsillectomy techniques are 
described.72,73 These include but are not limited to cold-steel dissection techniques, 
bipolar or monopolar electrocautery techniques, Coblation™ tonsillectomy, Bizact™ 
tonsillectomy or microdebrider assisted tonsillectomy.  Regardless of the technique, the 
principle includes the dissection of lymphoid tissue with or without their capsule while 
leaving behind the superior constrictor muscle fibres.  The mucosa and musculature of 
the palatopharyngeus muscle and palatoglossus muscle is usually left behind.  When 
considering a potential tonsil malignancy, it is important to consider significant diathermy 
artefact that may hinder the histological evaluation.  While there are no recommendations 
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available in the literature as to which tonsillectomy technique is superior in the presence 
of potential tonsil malignancy, certain techniques would be unsuitable in this setting, 
based on first principles.  For example, using microdebrider assisted techniques or 
Coblation™ techniques, more specifically intra capsular dissection, would not provide an 
adequately intact histological sample for further evaluation. 
Tongue base mucosectomy is another recognised procedure in the diagnostic 
process of HNCUP.74 Since the mid-2000s, the use of TORS technique to access the 
tongue base has gained popularity.  Small case series studies from the United Kingdom 
and Australia using TORS have reported tumour identification rates of 53% (n = 17) and 
71% (n = 7), respectively.74,75 Earlier studies using TORS from the United States of 
America (USA) have reported up to a 90% detection rate.65,76,77  A recent systematic 
review reported an improved primary detection rate (80%) using TORS or transoral laser 
microsurgery (TLM) if the whole examination process including palatine and lingual 
tonsillectomy was conducted with TORS/TLM compared to TORS tongue base 
mucosectomy alone (72%).78  Another meta-analysis reported a TORS/TLM primary 
detection rate of 70.8% (range: 53.1% – 90%) with 64% of primary tumours identified in 
base of tongue (BOT).79 However, they also reported a high positive margin rate of 22.8% 
(range: 15.4% to 48.6%) that negates some of the benefits of conducting a BOT 
mucosectomy as re-resection or irradiation of that mucosa would be necessary, adding to 
the morbidity of treatment. 
The mucosectomy technique involves dissecting away the mucosa and lymphoid 
layer (lingual tonsils) from the BOT; this can be done unilaterally or bilaterally.  However, 
bilateral mucosectomy puts the patient at risk of circumferential cicatrisation that may 
cause significant oropharyngeal stenosis.  Therefore, carefully considered surgical steps 
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are described, where tonsillectomy and mucosectomy are well clear of the tonsil-lingual 
sulcus, at least on a single side, preventing circumferential cicatrisation.74  The laterality 
of HNCUP is important to consider because contralateral primary tumour rates are 
reported to be approximately 6% and 15% for tongue base and palatine tonsil, 
respectively.78 
1.8.2 Non-surgical options 
Intensity-modulated radiation therapy (IMRT) and its variations, including 
volumetric-modulated arc therapy (VMAT), have become the preferred technique in 
radiation oncology approach to the treatment of HNSCC since the mid-2000s.80 Its 
popularity is primarily due to the advanced three-dimensional control of radiation 
intensity, which maintains the appropriate dosage at the tumour site while limiting toxicity 
to the surrounding tissue.80 The PARSPORT trial (parotid sparing intensity modulated 
versus conventional radiotherapy in head and neck cancer – multicentre randomised 
controlled trial)80,81 highlighted the superiority of IMRT in reducing radiation dosage to 
normal tissues and reducing the evidence of severe xerostomia.81  Irradiation of the 
potential primary tumour sites in addition to the neck however was associated with 
significantly more adverse events.9  A significant issue impacting the practical utility of 
this meta-analysis9 was the inclusion and combination of all studies published up to 2015;  
this included studies that used both IMRT and conventional radiotherapy, where the 
survival rates and adverse event profiles are notably significantly different with these 
techniques.81,82  Given the superior adverse events profile of IMRT and the relatively 
common use in head and neck setting today, the systematic review presented in this thesis 
will only include studies using IMRT (or an acceptable form of IMRT) to obtain a more 
homogeneous study population with comparable treatments. More recently, neoadjuvant 
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radiotherapy techniques have also been described more specifically for advanced stage 
oral cavity SCC.83 However, no neoadjuvant treatment paradigms are published relevant 
to the treatment of HNCUP. 
Systemic therapy is used in two clinical scenarios in relation to HNCUP: first, in 
the setting of improving locoregional control by addition of chemotherapy to primary or 
adjuvant radiotherapy;84  second, in the palliative care setting, where other modes of 
treatment have failed, or the presenting disease is locally advanced with distant 
metastasis.84  Use of chemotherapy in HNCUP was first described by de Braud et al.85 in 
1989, where the addition of concurrent chemotherapy during radiotherapy treatment 
significantly improved survival rates in advanced stages of disease (stage N3).  While 
some recent non-randomised studies indicate a survival benefit82,84 with an acceptable 
toxicity profile, others do not.86  Data is not available to show a definite advantage of 
systemic therapy, especially when the toxicity profile is considered. 
1.9 Endpoint measures in cancer research 
There are numerous cancer specific endpoints described in the literature.  However, 
the nomenclature used in various publications is inconsistent and at times misleading.  
Punt et al. 87 described consensus agreement of nine different endpoints in cancer research 
(Table 7).  Overall survival is commonly used as the gold standard endpoint for reporting 
treatment effectiveness in cancer research.  However, when considering head and neck 
cancers and comparing treatments, differences have been shown in other clinical 
endpoints despite there being no differences in overall survival.  This is also true for other 
cancer subsites such as colorectal and breast cancer studies.87  The consensus statement 
from Punt et al. 87 suggests the following definitions for cancer related outcome measures: 
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• Disease-free survival (DFS), defined as the time to any event (except loss to 
follow-up), regardless of the causative agent.  This includes recurrence of disease 
or death. 
• Relapse-free survival (RFS), defined as events such as recurrence or death from 
the same cancer, and death from treatment related to other causes.  However, it 
excludes events from the same type of second primary cancer or another type of 
primary cancer.  Failure to follow-up is censored in this metric.   
o In the context of head and neck cancer, regional relapse-free survival 
(RRFS) is defined as the time to disease recurrence at the site of tumour 
presentation or regional lymph nodes.   
• Progression free survival (PFS) is another endpoint measure in head and neck 
cancer research, where it is the interval from treatment completion recurrence in 
local, locoregional or distant organs.88 
• Cancer-specific survival (CSS) or disease-specific survival (DSS), defined as the 
time to death caused by the same cancer.  This includes the original tumour as 
well as any second primary tumours of the same type.  However, it excludes death 
from other types of cancers or treatment related events.  It also excludes 
recurrences or any other tumour related events.  Loss to follow-up is censored. 
• Overall survival (OS), defined as the time to death, regardless of the cause.  Any 
other tumour related event is excluded, with loss to follow-up censored like other 
end points. 
• Time to recurrence (TTR), defined as any event related to the cancer of interest.  
The emergence of recurrence or death related to the cancer of interest is 
considered an event.  Deaths related to other malignancies, comorbidities or 
treatment are censored. 
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• Time to treatment failure (TTTF), defined as the time to recurrence or death from 
any cancer or treatment.  Only non-cancer related deaths and loss to follow-up are 
excluded. 
An outcome measure specifically related to HNCUP is: 
• Primary emergence (PE), defined as the percentage of patients with a tumour 
appearing in a subsite known to have lymphatic drainage to the affected metastatic 
lymph node.  This is normally reported as a percentage event at five years 
following treatment. 
Table 7. Cancer specific time-to-event outcome measures and composition of each measure for 
determining effectiveness of treatment87 
Event DFS RFS TTR TTF CSS OS 
Locoregional recurrence E E E E I I 
Distant metastasis E E E E I I 
Second primary, same cancer E I I E I I 
Second primary, other cancer E I I E I I 
Death from same cancer E E E E E E 
Death from other cancer E E C E C E 
Non-cancer related death E E C C C E 
Treatment related death E E C E C E 
Loss to follow-up C C C C C C 
DFS = disease-free survival, RFS = relapse-free survival, TTR = time to recurrence, TTF = time to treatment failure, 
CSS = cancer specific survival, OS = overall survival, E = event, I = ignore, C = censor 
1.10 Toxicities and quality of life with treatment of HNSCC and their 
measurement 
Despite advances in the delivery of surgery, radiation oncology and medical 
oncology, patients continue to suffer from significant adverse events and long term 
toxicity.89  Therefore, it is important to consider quality of life (QoL) for these patients.  
The World Health Organization (WHO) defines QoL as the person's perception of their 
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own position in life, within the context of their culture and value systems, related to their 
goals, expectations, standards and concerns.90  As the definition suggests, the concept of 
QoL is complex, where the general wellbeing of a person is quantitatively or qualitatively 
assessed from multiple perspectives, relevant to a particular context in the patient’s life.91  
In the context of head and neck cancer, adverse events are directly related to the modality 
of treatment received and the stage of their cancer.   
For patients treated with primary surgery, adverse events or toxicities can be 
categorised into peri-operative, intra-operative, immediate post-operative and late 
complications.  General anaesthesia is a requirement for head and neck surgery and 
patient comorbidities can result in adverse events, including death.  However, anaesthetic 
complications are beyond the scope of this review and therefore are not further discussed.  
Intra-operatively, various vital structures within the neck are exposed and there is 
potential for injury.  One of the most common symptoms reported following a neck 
dissection is limited shoulder abduction or pain secondary to injury of spinal accessory 
nerve.  In modern day neck dissections, this nerve is preserved.92  Other named neural 
structures with potential injury include the vagus nerve, lingual nerve, hypoglossal nerve 
and the marginal mandibular nerve.  In very rare cases where the tumour is invading deep 
into the root of the neck, there is potential to injure the brachial plexus (innervate the 
upper limb) as well as the phrenic nerve that innervates the diaphragm.  Other intra-
operative complications include vascular injury (venous or arterial and related air emboli), 
pneumothorax and chyle leak (due to thoracic duct injury).  Potential post-operative 
complications range from wound infections,93 wound dehiscence, hypertrophic or poorly 
aesthetic scar, haematoma, seroma and lastly carotid blow out injury secondary to tumour 
invasion to the carotid artery or adventitial injury during neck dissection.94  Most post-
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operative complications are minor and managed conservatively.95  However, in rare cases, 
return to theatre is necessary. 
For patients treated with radiation alone or combined chemoradiation, the most 
prevalent acute toxicity is high-grade mucositis.96  According to Givens et al.,96 other 
common complications related to chemoradiation include, haematological toxicity, 
desquamation, neurotoxicity, ototoxicity, dehydration, malnutrition, pneumonia, trismus, 
osteoradionecrosis and febrile episodes.   
Trotti et al.,97 describes TAME (Toxicity, Adverse long-term effects, Mortality risk 
and End result) as a validated method of reporting adverse events to allow for useful 
clinical decision making.  Adverse events described above directly contribute to health-
related quality of life outcomes (HRQoL).  In the context of head and neck cancer, the 
domains of interest for HRQoL include speech, eating, aesthetics, physical health, mental 
health and social disruption.96  However, dysphagia, xerostomia and voice outcomes 
dominate the literature as long-term complications of both surgical and radiotherapy 
treatment modalities.98-101   
Various reporting tools are described in the literature to quantify HRQoL.102,103  The 
most recent systematic review of literature by Klein et al.103 identified 18 high quality 
studies describing four validated HRQoL measurement tools.  The most commonly 
utilised tools were the European Organisation for Research and Treatment of Cancer 
(EORTC) Quality of Life Questionnaire (QLQ-C30 and HN-35 module), the University 
of Washington Quality of Life Questionnaire (UWQOL), and the Functional Assessment 
of Cancer Therapy Head and Neck Cancer questionnaire (FACT-H&N).103  More 
specifically for assessment of dysphagia, the MD Anderson Dysphagia Inventory 
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(MDADI)104 and the Functional Oral Intake Scale (FOIS) were widely used.105  In the 
current literature, voice related outcomes for adult patients are reported using the Voice 
Handicap Index (VHI),106 the abbreviated VHI-10107 and the Voice-Related Quality of 
Life Measure (V-RQOL).108  All three tools are validated patient reported outcome 
measure tools to specifically assess voice-specific functional status.108-110. 
1.11 Overview of systematic review methodology and evidence synthesis 
There are multiple retrospective case series and cohort studies investigating the 
effectiveness of one treatment modality over others for HNCUP, however, no randomised 
datasets are available.  A preliminary search of the Cochrane Library, PubMed, Embase 
and the JBI Database of Systematic Reviews and Implementation Reports found no 
published systematic reviews or protocols that directly investigate the effectiveness of 
primary surgery versus primary radiotherapy for the treatment of HNCUP.  A systematic 
review by Liu et al.9 was identified during the formal search process,  hence the decision 
to systematically review available literature. 
In 1979 a method of documenting levels of evidence was described by a Canadian 
Task Force.  A three-tier rating scale of evidence was implemented to determine the 
effectiveness of periodic health examination for specific medical conditions.111  Since 
then, multiple modifications have been made to the method of documenting evidence in 
health care settings.  For example, Sackett et al.112 added two further tiers to rate evidence 
in a scale of 1 to 5.  They also defined evidence-based health care as decisions made 
regarding the care of individual patients based on the best available evidence.112  
Appropriate evidence synthesis of multiple studies allows for the estimation of true effect 
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compared to a single study.113  Herein lies the importance of a well conducted systematic 
review. 
Reproducibility and a rigorous approach to identifying primary research and 
subsequent critical appraisal of the quality of research allows for synthesis of evidence to 
form a systematic review with or without the meta-analysis of data.  Systematic reviews 
and synthesis of multiple, well-designed, double-blind randomised controlled trials 
(RCTs) provide ideal datasets for guiding evidence based clinical practice to evaluate the 
effectiveness of an intervention or therapy.  While randomised datasets minimise bias and 
confounding, the conduct of RCTs is not always clinically safe or logistically possible or 
feasible.  However, evidence synthesis is required to promote evidence-based clinical 
practice and the development of clinical practice guidelines, regardless of presence of 
RCTs.  A systematic review achieves a high-quality data synthesis by first having an a 
priori protocol detailing the search methodology and selection criteria.114  This pre-
defined, peer reviewed publication of the a priori protocol allows for bias minimisation 
and effective guidance of the conduct of the review.113,115  Interestingly, a recent study 
found that systematic reviews with a published protocol had superior reporting of 
methodology and findings while taking longer from search to result submission.115  
Registration of ongoing systematic reviews similar to the registration of ongoing clinical 
trials is another method of bias minimisation, allowing for a priori publication and public 
scrutiny of the methodology. The Prospective Register of Ongoing Systematic Reviews 
(PROSPERO) an international advisory group in collaboration with UK National 
Institutes of Health Research, allows for free registration of ongoing systematic reviews 
online.  Sideri et al.116 reported a superior quality of reviews registered in PROSPERO 
compared to non-registered reviews using the Assessment of Multiple Systematic 
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Reviews (AMSTAR) tool.  The protocol for this review was published117 on a peer 
reviewed journal as well as registered on PROSPERO (CRD42018089182) 
Quality evidence synthesis that can inform clinicians and patients about diagnostic 
or treatment options based on available best evidence is an important step prior to the 
development of clinical practice guidelines (CPG).  A CPG should make strong 
recommendations to influence clinical decision making and is based on the quality of 
available evidence.  The Grades of Recommendation, Assessment, Development and 
Evaluation (GRADE) working group has developed a system for grading the certainty of 
the evidence and strength of recommendations.118 A comprehensive list of already 
established evidence based healthcare organisations have adopted and endorsed the use 
the GRADE system, including Cochrane and the WHO.118  The main advantages of using 
the GRADE system is the clear separation between quality of evidence and strength of 
recommendation, explicit criteria for downgrading or upgrading quality of evidence, 
consideration of various outcomes to patients, explicit advice to make recommendations 
(even when very little evidence is available), clear pragmatic interpretation of strong or 
weak recommendations, and having a balance between methodological 
comprehensiveness and simplicity of reporting.118 
In the setting of HNCUP, the low incidence of disease occurrence does not permit 
for practical and timely prospective trials.  Hence, the majority of studies are based on 
retrospective review of patient databases.  In light of this, a well conducted systematic 
review using the GRADE approach to determine the certainty of the evidence would 
increase the likelihood of informing and influencing current clinical practice. 
  
 
2 CHAPTER 2: METHODS 
2.1 Types of participants 
Participants included adults (aged 18 years or older) who had undergone treatment 
with curative intent for an HNCUP.  All stages of tumours were included. 
2.2 Types of interventions 
This review included studies comparing surgery to radiotherapy as the primary 
intervention with curative intent.  Surgery included any form of a neck dissection 
conducted as the primary treatment. Types of neck dissections considered included 
MRND or SND.  Excisional node biopsy was not considered as a primary surgical 
treatment as this is only recommended for diagnostic purposes in non-SCC head and neck 
pathologies.  In addition to the neck dissection, tongue base mucosectomy with TORS 
with bilateral or unilateral tonsillectomy was also included as a primary surgical 
treatment.  Patients with planned adjuvant radiotherapy (radiotherapy alone or concurrent 
chemoradiation) following primary surgery were also included.  Only studies that 
specifically utilised IMRT (see Section 1.8.2) or related techniques were included. 
Patients who had salvage surgery following primary radiotherapy were included if 
there was adequate description of survival and QoL prior to salvage surgery as salvage 
surgery would be considered the point of primary treatment failure.  When a study 
specified a planned neck dissection within a specified period following primary 
radiotherapy, this data was included.  Studies with concurrent or induction chemotherapy 




This review considered studies that included the following outcomes: 
2.3.1 Primary outcomes: 
This review examined OS and RRFS as primary outcome measures.  These outcome 
measures were further categorised according to the relationship between rates of primary 
neck dissection, diagnostic paradigm and staging.  In order to substantiate the survival 
outcomes, the primary tumour emergence, neck failure (residual or recurrent disease in 
the neck) and distant metastasis percentages were also extracted.  Descriptions of these 
outcome measures are detailed in Section 1.9. 
2.3.2 Secondary outcomes: 
• QoL following treatment: measured with validated tools for QoL (e.g. TAME, 
HRQoL, QLQ-C30, UWQOL, FACT-H&N, MDADI, FOIS, V-RQOL and VHI), 
mainly related to xerostomia, swallowing and voice outcomes.  See section 1.10 
for descriptions of these tools. 
• Toxicities commonly reported following cancer treatment: dysphagia, 
xerostomia, mucositis and other end organ complications 
2.4 Types of studies 
This review considered both experimental and quasi-experimental study designs 
including RCTs and non-RCTs. In addition, analytical observational studies including 
prospective and retrospective cohort studies and case series were considered for inclusion.  
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Studies published from 2005 were included as the technology used in radiation oncology 
has significantly changed since then, causing less toxicity.9 Also, the use of the TORS has 
become more common since 2005. 
2.5 Search strategy 
The search strategy aimed to locate both published and unpublished studies. An 
initial, limited search of PubMed was undertaken (on 6th May 2017), followed by an 
analysis of the text words contained in the titles and abstracts, and of the index terms used 
to describe the article.  This informed the development of a search strategy which was 
tailored for each information source (PubMed, Embase, ProQuest (Dissertations and 
Theses), ClinicalTrials.gov, International Clinical Trials Registry Platform, Canadian 
Cancer Trials, Australian New Zealand Clinical Trials Registry, European Union Clinical 
Trials Register, Chinese Clinical Trial Register, Clinical Research Information Service – 
Korea, Clinical Trials Registry India, Cuban Public Registry of Clinical Trials, Iranian 
Registry of Clinical Trials, Japan Primary Registries Network and Pan African Clinical 
Trial Registry).  This search strategy was submitted for peer review as part of the a priori 
protocol.117  A full search strategy for PubMed, Embase and ProQuest databases is 
detailed in Appendix I.  Search of trial registries and journal databases (PubMed, Embase 
and ProQuest) were conducted on 4th December 2017.  The reference lists of studies 




2.6 Study selection 
Following the search, all identified records were collated and uploaded into 
EndNote Version x9.1 (Clarivate Analytics, PA, USA) and duplicates were removed. 
Titles and abstracts were screened by a single reviewer (ND) for assessment against the 
inclusion criteria for the review. Full text of studies that met the inclusion criteria were 
retrieved,  their details were imported into Joanna Briggs Institute System for the Unified 
Management, Assessment and Review of Information (JBI SUMARI),119 and assessed in 
detail against the inclusion criteria of the review (Sections 2.1-2.4). Full-text studies that 
did not meet the inclusion criteria were excluded and reasons for exclusion are provided 
in Appendix I.  
2.7 Critical appraisal 
Selected studies were critically appraised by two independent reviewers (ND and 
MM) at the study level for methodological quality in the review using the standardised 
critical appraisal instrument for cohort studies from the Joanna Briggs Institute.119  Minor 
disagreements were resolved with discussion and a third reviewer was not required for 
further independent appraisal.  None of the studies were excluded based on critical 
appraisal. 
2.8 Data extraction 
Data of interest were extracted from articles by a single reviewer (ND) using 
Microsoft Excel®. The extracted data included specific details about the interventions, 
participants, study methods and outcomes of significance (see Sections 2.1-2.4) to the 
review question and specific objectives.  Authors of these studies were contacted to 
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request missing or additional data (see Appendix II).  However, none of the corresponding 
authors contacted provided additional data and only one corresponding author for Kamal 
et al.120 responded. 
2.9 Data synthesis 
Meta-analysis was conducted using Review Manager (RevMan®) version 5.3.121  
Effect sizes are expressed as hazard ratios (HR) and their respective 95% confidence 
intervals.  Heterogeneity was assessed and reported using the standard chi-squared (χ2) 
test and I squared (I2) statistic. I2 value of less than 40% was considered an acceptable 
level of heterogeneity for further interpretation of pooled data, where as an I2 of more 
than 75% was consistent with considerable heterogeneity.122  The I2 statistic was 
interpreted along with the associated confidence intervals, magnitude and direction of 
effects and the significance testing based on χ2.  A low p-value from the χ2 test as well as 
poorly overlapping confidence intervals would indicate the presence of heterogeneity.  A 
p-value less than 0.10 was used for consideration of statistical significance because the 
studies included in this review had relatively low sample sizes.122  Therefore, a non-
significant result in isolation was not considered to have no heterogeneity.  A random 
effects model was used for meta-analysis as we were not able to confidently assume that 
each study was estimating an equal number of effects and that at least minor heterogeneity 
was observed.123  Subgroup analysis could not be performed as intended a priori 117 based 
on TORS mucosectomy or HPV status due to lack of stratified reporting of data.  Hazard 
ratio (HR) was calculated as the summary statistic for five studies included in the meta-
analysis.  The five studies included for meta-analysis did not provide summary statistics 
for direct comparison.  Therefore, the HR was calculated using the method described and 
worksheet provided by Tierney et al.124  that calculated the HR for each comparison (see 
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Appendix III). In brief, HRs were calculated based on published Kaplan-Meier plots (see 
Appendix III for an example) and the number of at risk patients provided for time intervals 
between year 1 and 5 after treatment using the method described by Tierney et al.124  The 
accuracy of estimation using this method is increased when the number of patients at risk 
for the time period of interest is provided as part of the Kaplan-Meier plot (see Appendix 
III). 
Where statistical pooling was not possible, non-parametric Spearman rank-order 
correlation and linear regression analysis were conducted to identify interdependent 
relationships using GraphPad Prism Version 8.0 (GraphPad Software, CA, USA).  Data 
not suitable for statistical analysis are presented in narrative form including tables and 
figures to aid in data presentation, where appropriate.  Funnel plots were not generated as 
less than ten studies were included in the meta-analysis.122 
2.10 Assessing certainty 
A 'Summary of Findings' table was created using GRADEPro GDT Version 3.0 
(McMaster University, ON , Canada).125  The 'Summary of Findings' table presents the 
HR for OS and RRFS, for the comparison between primary treatment modalities, and a 
ranking of the quality of the evidence based on study limitations (risk of bias), 




3 CHAPTER 3: RESULTS 
3.1 Study identification and inclusion 
Following database searching and removal of duplicates, 9376 unique records were 
available for screening (Figure 2).  Title and abstract review (see Section 2.6) identified 
83 studies for full text retrieval and review.  Following full text review, a further 68 studies 
that did not meet the inclusion criteria were excluded.  Specific reasons for these 
exclusions are listed in Appendix I (see Section 6.1).  Ultimately, 10 studies were included 
in this systematic review. 
 
Figure 2. Flow diagram illustrating the process of study inclusion in this systematic review. 
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3.2 Critical appraisal of included studies 
Ten retrospective cohort studies underwent independent critical appraisal by two 
independent reviewers (Table 8).  Overall, the quality of the included studies was poor.  
Patients in all studies had a neck metastasis from an unknown primary tumour prior to 
commencing treatment, therefore, the comparison groups were recruited, albeit 
retrospectively, from the same disease population (Question 1).  Interventions were 
administered similarly and in a valid and reliable way in all included studies (Questions 
2 and 3).  Only three studies98,99,102 identified and reported confounding factors in detail; 
the majority of studies had unclear descriptions of identifying or including confounding 
factors in their analyses (Question 4).126-128  Therefore, strategies for dealing with 
confounding factors were not clearly stated or identifiable in any of the included studies 
(Question 5).  Outcomes were measured in a valid and reliable manner, with adequate 
follow-up time for the outcome to occur in all studies (Questions 6, 7 and 8).  However, 
these studies failed to consistently report on five-year survival outcomes that affected the 
ability to comment on long-term survival outcomes and led to the inability to conduct a 
pooled data analysis.  However, the reported time intervals were acceptable from a 
clinical point of view, given the retrospective nature of studies included.  Outcomes were 
analysed with appropriate statistical analysis (Question 11).  However, only five articles 
reported survival and toxicity outcomes, stratified according to primary treatment 
modality.88,120,126,129,130  Due to the retrospective nature of all included studies, follow-up 
was not complete and further strategies to address incomplete follow-up were not 




Table 8. Critical appraisal of included studies using JBI Critical Appraisal Checklist for Cohort 
Studies (Appendix I) 
Citation Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 
Amsbaugh88 Y Y Y N N Y Y Y U U Y 
Chen131 Y Y Y U U Y Y Y U U Y 
Demiroz126 Y Y Y Y U Y Y Y U U Y 
Frank127 Y Y Y Y N Y Y Y U U Y 
Huo129 Y Y Y U U Y Y Y Y U Y 
Kamal120 Y Y Y N N Y Y Y Y U Y 
Klem80 Y Y Y U U Y Y Y U U Y 
Lu6 Y Y Y U U Y Y Y U U Y 
Madani128 Y Y Y Y U Y Y Y Y U Y 
Mizuta130 Y Y Y U U Y Y Y Y U Y 
Yes % 100 100 100 27.3 0.0 100 100 100 36.4 0.0 100 
Q = Question, Y = Yes, N = No, U = Unclear  
3.3 Characteristics of included studies 
3.3.1 Geographical location  
Geographical location is likely to influence the rate of occult skin malignancies 
presenting as HNCUP because in Caucasian populations, the level of ultraviolet light 
exposure via sunlight is directly proportional to the incidence of skin HNSCC.  Australia 
is geographically a high-risk nation for skin malignancies.132  However, only one study 
included in this review was conducted in Australia129  Figure 3 shows the geographical 
distribution of the studies included in this review. Seven studies were from the USA, 
where parts of this country are at high-risk of non-melanoma cutaneous malignancies.  
They included patients from the following states: Texas,120,127 Michigan,126 Iowa,6 New 
York,80 California131 and Kentucky.88  The remaining studies were from Japan,130 




Figure 3. Geographical location of patients recruited for studies included in this review.  Each 
red dot represents an individual study, except for Houston and Texas, USA, where two of the study 
populations were recruited. 
3.3.2 Study participants 
The combined sample size was 655 participants from 10 studies (Table 9).  These 
studies included patients diagnosed with a HNCUP between the years 1991 to 2015.  The 
overall median age of patients was 58 years, ranging from 19 to 89 years, with a skewed 
Gaussian distribution towards the older age group.  There was a large male predominance, 
with five to one male to female representation. 
Table 9. Population characteristics of included studies 
Author Year n pND (%) pRT (%) Age (range) Gender (%F) 
Chen131 2018 31 10 (32%) 21 (68%) 60 (45 – 71) 7 (24%) 
Huo129 2018 63 37 (59%) 26 (41%) 64 (35 – 88) 8 (13%) 
Kamal120 2018 260 79 (30%) 181 (70%) 58 (19 – 84) 39 (15%) 
Mizuta130 2018 80 41 (51%) 12 (15%) 65 (39 – 83) 18 (23%) 
Amsbaugh88 2017 66 37 (56%) 29 (44%) 56 (21 – 83) 13 (20%) 
Demiroz126 2014 41 22 (54%) 19 (46%) 53 (38 – 72) 4 (10%) 
Frank127 2010 52 13 (25%) 39 (75%) 56 (NR) 6 (12%) 
Lu6 2009 18 12 (67%) 6 (33%) 55 (37 – 89) 2 (11%) 
Klem80 2008 21 16 (76%) 5 (24%) 57 (39 – 80) 4 (19%) 
Madani128 2008 23 19 (83%) 4 (17%) 61 (47 – 85) 6 (26%) 
Overall  655 286 (44%) 342 (52%) 58 (19 – 89) 109 (17%) 
Median age is reported; Year = year of publication; n = total number of participants; pND = primary neck dissection; 
pRT = primary radiotherapy; NR = not reported; F = female 
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These patients had neck nodal SCC that ranged from stages 1 to 3, based on the 
seventh edition of AJCC cancer staging manual (Section 1.6).  The predominant nodal 
stage was N2b (294 patients, 46%), followed by N2a (131 patients, 20%), N1 (97 patients, 
15%), N3 (66 patients, 10%) and N2c (55 patients, 9%), respectively (Table 10).  Three 
studies reported the nodal stage distribution between treatment paradigms.88,126,129  Four 
studies reported the p16 status for their respective cohorts.120,126,129,131  However, only one 
study tested all their patients for p16 status as well as cross validating these patients with 
in situ hybridisation technique for HPV DNA positivity.131 
Table 10. Neck nodal staging distribution based on primary treatment modality and p16 status 
Author Tx N1 N2a N2b N2c N3 p16+ 
Chen131 pND       
 pRT       
 All 5 11 9 0 0 10 
Huo129 pND 11 8 18 0 0 *0 
 pRT 1 7 15 0 3 *14 
 All 12 15 33 0 3 *14 
Kamal120 pND       
 pRT       
 All 26 40 141 31 22 *90 
Mizuta130 pND       
 pRT       
 All 15 16 34 5 10 NR 
Amsbaugh88 pND 10 6 12 5 4  
 pRT 5 9 6 3 6  
 All 15 15 18 8 10 NR 
Demiroz126 pND 2 6 8 0 6 *10 
 pRT 2 4 10 0 3 NR 
 All 4 10 18 0 9 *10 
Frank127 pND       
 pRT       
 All 8 10 18 6 4 NR 
Lu6 pND       
 pRT       
 All 0 8 7 2 1 NR 
Klem80 pND       
 pRT       
 All 9 0 8 1 3 NR 
Madani128 pND       
 pRT       
 All 3 6 8 2 4 NR 
Overall (%)  97 (15%) 131 (20%) 294 (46%) 55 (9%) 66 (10%) *124 (19%) 
Tx = primary treatment, pND = primary neck dissection, pRT = primary radiotherapy, N = neck staging, NR = not 




Two studies120,129 considered and analysed separately the cutaneous origin of nodal 
SCC.  Kamal et al. 120 identified patients with high risk of cutaneous origin of SCC and 
excluded these patients from further analysis.  Huo et al.129 identified patients with high 
risk of a cutaneous primary SCC and the treatment paradigm was stratified according to 
their risk and outcomes presented accordingly.  The remaining studies in this review did 
not specifically report any consideration of HNCUP with potential cutaneous origin. 
3.3.3 Study design and interventions  
All ten studies included in this systematic review were retrospective cohort studies, 
with samples largely taken from retrospective interrogation of cancer databases.  All, 
except for Kamal et al.120 Frank et al.127 and Lu et al.,6 treated the majority of their 
patients with a primary neck dissection (Table 11), followed by adjuvant radiotherapy 
alone or adjuvant concurrent chemo-radiotherapy.  The remaining three studies6,120,127 
principally treated their patients with primary radiotherapy (pRT) as per local guidelines, 
with only a small group of patients receiving a planned neck dissection.  Other treatment 
options included pRT alone, primary concurrent chemo-radiotherapy, neck dissection 
alone, or primary radiotherapy followed by pND. 
The two studies from MD Anderson Cancer Center,- Kamal et al.120 and Frank et 
al.,127 treated the majority of their patients with primary IMRT 84% and 58%, respectively.  
Lu et al.6 similarly treated the majority of their patients with primary IMRT (56%). In 
Australia, Huo et al.129 treated all suspected cutaneous primary patients with a pND 
(100%) and suspected mucosal primary patients with mainly primary IMRT (88%).  Neck 
dissection alone was performed in 27 patients reported by Mizuta et al.130  None of the 
other studies provided neck dissection only as a treatment option to their patients.  
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Demiroz et al.126 and Kamal et al.120 treated patients with a pND after pRT in 5% and 1% 
of their respective patient cohorts. Only four studies88,126,129,130 described the treatment 
modality based on nodal staging with the majority of these cases being treated with 
primary neck dissections.  Overall, N1, N2a, N2b, N2c and N3 were treated with primary 
surgery 80%, 64%, 67%, 84% and 59% of the time, respectively. 
Tonsillectomy was described as part of the diagnostic pathway in four studies 
88,120,127,131 and tongue base mucosectomy (with or without TORS) in only one study.131  
Bilateral tonsillectomy was described in most cases.  However, Chen et al. treated all 
patients with an ipsilateral tonsillectomy and Frank et al. treated 10% of patients with an 
ipsilateral tonsillectomy.  Base of tongue mucosectomy was only done in three patients 
(overall only 0.4%) in the study by Chen et al.131  While two other studies mentioned 
tongue base biopsies, they did not describe a tongue base mucosectomy.88,120 
3.3.4 Length of follow-up 
Due to the retrospective nature of the studies included, the median follow-up time 
varied significantly between the studies of interest, ranging from 17 to 73 months (Table 
11).  Demiroz et al.126 did not report an overall follow-up time, instead providing a 
stratified follow-up time based on treatment modality.  The median follow-up time for 
Amsbaugh et al.,88 Chen et al.,131 Klem et al.80 and Madani et al.128 was less than 24 
months.  While these studies had some patients followed up for longer than five years, 
the data from patients followed up for less than 24 months is likely to add bias to Kaplan-
Meier estimates of survival reported in these studies (see Section 2.9).  This is an inherent 
limitation of retrospective studies with small sample sizes. 
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Table 11. Median follow-up time for included studies 
Author Follow-up - median months (range)  
Amsbaugh88 22 (0.2 – 125.2) 
Chen131 21 (6 – 61) 
*Demiroz126 39 (11 – 98) RT 73 (18 – 126) ND+RT 
Frank127 44 (12 – 91.2) 
Huo129 47 (IQR 24.8 – 61.7) 
Kamal120 61 (0 – 176) 
Klem80 20 (5 – 21) 
Lu6 26 (6.5 – 86.3) 
Madani128 17 (2 – 39) 
Mizuta130 34 (2 – 132) 
*Demiroz et al. did not provide an overall median follow-up value, RT = radiotherapy, ND = neck dissection, IQR= 
interquartile range 
3.4 Primary outcomes 
3.4.1 Overall survival 
OS was reported in all studies for the whole cohort except Demiroz et al.126 
Furthermore, only five studies83,112,118,121,122 reported OS based on primary treatment 
modality (Table 12).   The maximum reported five-year OS was 92% for the pND group 
in Kamal et al.120 (Table 12).  The maximum reported two-year OS was 93% for the pRT 
group in Demiroz et al.126  As mentioned earlier, due to the retrospective nature of these 
studies, the follow-up period was variable and therefore the reporting year of survival was 
not readily comparable.  Two studies that provided a five-year OS between primary 
treatment modalities had a 10%- 13% difference in five-year overall survival that was not 
statistically significant (p > 0.05).  Meta-analysis of five studies that provided stratified 
survival data based on primary treatment modality did not show a statistically significant 
result (p = 0.60) towards a particular treatment modality.  Analysis of heterogeneity in 
this analysis was surprisingly low (Figure 4, I2 of 32%, p = 0.21).  There was a poor linear 




Table 12. Overall survival based on primary treatment modality 
Author HR (95% CI) Primary Tx 1 year 2 years 3 years 4 years 5 years 
Amsbaugh88 0.77 (0.26-2.30) ND+RT±C - - 63.9% - - RT±C - - 59.8% - - 
Demiroz126 1.6 (0.22-11.41) ND+RT±C - 90.7% - 85.3% - RT±C - 93.3% - 85.6% - 
Huo129 1.68 (0.58-4.90) ND+RT±C - - - - 66.0% RT±C - - - - 79.6% 
Kamal120 0.43 (0.21-0.87) ND+RT±C - - - - 92% RT±C - - - - 82% 
Mizuta130 1.05 (0.37-3.00) ND+RT±C - - 71.9% - - RT±C - - 83.3% - - 
ND = neck dissection; RT = radiotherapy; C = chemotherapy; Tx = treatment; HR = hazard ratio; CI = confidence 
interval 
 
Figure 4. Meta-analysis of overall survival from five studies directly comparing and reporting 
overall survival outcomes based on primary treatment modality.  Calculated two-year overall 
survival data from Table 10 used for this analysis. ND = Primary neck dissection, RT = Primary 
radiotherapy. 
 
Table 13. Overall survival of participants having a primary neck dissection 
Author ND 1 year 2 years 3 years 4 years 5 years 
Kamal112 16%  92%   84% 
Frank119 25%  ***81%   81% 
Chen123 32%  92%    
Lu6 44%  74.2%   *64% 
Mizuta122 51%  ***72.5% 72.5%   
Demiroz118 54%  **92%  **85%  
Amsbaugh84 56%  ***69.4% 69.4%   
Klem76 62% *85% 85% *85% *85% *85% 
Huo121 63% 96.6% 85.5% *75% *75% 71.2% 
Madani120 83%  74.8% *50%   
Overall 51±21%  78±14%    
*Estimated based on published Kaplan-Meier Graphs (Appendix III), **Estimated based on average survival rates, 





Figure 5. The relationship between two-year overall survival and percentage of patients who 
received a primary neck dissection in each study. 
 
Table 14 indicates the percentage of patients who received a tonsillectomy, tongue 
base mucosectomy or an fluorodeoxyglucose positron emission tomography (FDG-PET) 
scan as a part of their diagnostic paradigm, compared to their two-year OS.  Only three 
studies88,129,131 reported on whether or not a tongue base mucosectomy was conducted, 
ranging from 0%-100%.  Amsbaugh et al.88 was the only study reporting a 100% 
adherence to tonsillectomy and tongue base mucosectomy during the diagnostic phase.  
Six studies6,88,120,126,129,131 reported whether a tonsillectomy was conducted, and seven 
studies6,80,88,128-131 reported whether an FDG-PET scan was conducted during their 
diagnostic phase.  The percentage of patients who had an FDG-PET scan (Figure 6A, R2 
= 0.086, p = 0.5208) or a tonsillectomy (Figure 6B, R2 = 0.3321, p = 0.2313) during the 
diagnostic phase did not have a statistically significant linear relationship to OS (Figure 
7). 
  






















Table 14. Overall survival of participants and diagnostic criteria 
Author Tonsillectomy Mucosectomy FDG-PET 2-year 
overall 
survival 
Amsbaugh84 100% 100% 57.6% ***69.4% 
Chen123 100% 10% 100% 92% 
Demiroz118 49% NR NR **92% 
Frank119 NR NR NR ***81% 
Huo121 41% 0% 41% 85.5% 
Kamal112 55% NR NR 92% 
Klem76 NR NR 95% 85% 
Lu6 100% NR 86% 74.2% 
Madani120 NR NR 57% 74.8% 
Mizuta122 NR NR 87% ***72.5% 
*Estimated based on published Kaplan-Meier Graphs, **Estimated based on average survival rates, ***Estimated on 
worst case scenario based on published data, FDG-PET: fluorodeoxyglucose positron emission tomography 
 
 
Figure 6. The relationship between two-year overall survival and percentage of patients who had 
a fluorodeoxyglucose positron emission tomography (FDG-PET) scan (graph A) or tonsillectomy 
(graph B) prior to treatment. 
3.4.2 Regional relapse free survival 
RRFS was reported by all studies except Huo et al.129 and Madani et al.128 for their 
respective cohorts.  However, only three studies88,126,130 reported RRFS stratified based 
on primary treatment modality (Table 15).  The maximum reported four-year RRFS was 
76%126 for pND and the maximum reported three-year RRFS was 82%88 also for pND.  
Meta-analysis of RRFS for the studies that provided stratified values was not statistically 
significant (p = 0.07), with no significant heterogeneity amongst these studies (Figure 8, 
I2 = 0%, p = 0.78). 












































Table 15. Reported regional relapse free survival based on primary treatment modality 
Author HR (95% CI) Primary Tx 1 year 2 years 3 years 4 years 5 years 
Amsbaugh88 0.44 (0.18-1.12) ND+RT±C - - 82.2% - - RT+C - - 46.4% - - 
Demiroz126 0.73 (0.20-2.60) ND+RT±C - - - 76.1% - RT±C - - - 75.0% - 
Mizuta130 0.66 (.25-1.77) ND+RT±C - - 77.9% - - RT±C - - 66.7% - - 




Figure 7. Meta-analysis of regional relapse free survival for three studies directly comparing and 
reporting regional relapse free survival outcomes based on primary treatment modality.  ND = 
primary neck dissection, RT = primary radiotherapy, CI = confidence interval. 
 
The maximum reported two- and five-year RRFS for all study cohorts was 92%120 
and 94.2%,127 respectively (Table 16).  There was no statistically significant linear 
relationship between percentage of patients who underwent a pND and two-year RRFS 
(Figure 8, R2 = 0.02479, p = 0.664). 
Table 16. Whole cohort regional relapse free survival and percentage of participants having a 
primary neck dissection 
Author ND 1 year 2 years 3 years 4 years 5 years 
Amsbaugh84 56% *90% *82% *78.6% *78.6% 78.6% 
Chen123 32% *96 91% *91% *91% *91% 
Demiroz118 54% *100% *76% *76% *76% *76% 
Frank119 25% *100% *94.2% *94.2% *94.2% 94.2% 
Huo121 63% NR NR NR NR NR 
Kamal112 16% ***92% 92% ***91% ***91% 91% 
Klem76 62% *85% 85% *85%   
Lu6 44% *88.5% 88.5% *88.5% *88.5% *88.5% 
Madani 83% NR NR NR NR NR 
Mizuta122 51% ***74.0% ***74.0% 74.0%   
*Estimated based on published Kaplan-Meier Graphs, **Estimated based on average survival rates, ***Estimated on 





Figure 8. Relationship between two-year regional relapse free survival and percentage of patients 
treated with a primary neck dissection. 
Table 17 displays the percentage of patients who had a tonsillectomy, tongue base 
mucosectomy or FDG-PET scan during the diagnostic phase, compared to two-year 
RRFS.  Similar to OS results above, there were no statistically significant linear 
relationships between FDG-PET scan (Figure 9A, R2 = 0.1264, p = 0.5571) or 
tonsillectomy (Figure 9B, R2 = 0.0073, p = 0.5964) and two-year RRFS. 
 
Figure 9. Relationship between two-year regional relapse free survival and percentage of patients 
who had an fluorodeoxyglucose positron emission tomography (FDG-PET) (graph A) or 
tonsillectomy (graph B) scan prior to treatment. 
 
Table 17. Two-year regional relapse free survival in participants who had a tonsillectomy, 
mucosectomy or fluorodeoxyglucose positron emission tomography as a diagnostic test prior to 
treatment initiation 
Author Tonsillectomy Mucosectomy FDG-PET 2-year RRFS 
Amsbaugh84 100% 100% 57.6% *82% 
Chen123 100% 10% 100% 91% 
Demiroz118 49% NR NR *76% 
Frank119 NR NR NR *94.2% 
Huo121 41% 0% 41% NR 
Kamal112 55% NR NR 92% 
Klem76 NR NR 95% 85% 
Lu6 100% NR 86% 88.5% 
Madani120 NR NR 57% NR 
Mizuta122 NR NR 87% ***74.0% 




















































































Percentages represent the rate specific for each study that reported a tonsillectomy, mucosectomy or FDG-PET scan, 
*Estimated based on published Kaplan-Meier Graphs, ***Estimated on worst case scenario based on published data. 
NR = not reported; FDG-PET = fluorodeoxyglucose positron emission tomography; RRFS = regional relapse free 
survival 
Two studies120,130 reported regional and relapse free survival based on the neck 
nodal staging.  Both of these studies considered low neck stages to be inclusive of N1 to 
N2a and high neck stages to be inclusive of N2b and N3 stages.  Meta-analysis of these 
two studies indicated a clear benefit (p = 0.0002) of having lower neck stage for regional 
and relapse free survival regardless of the primary treatment modality.  There was 
minimal heterogeneity in this comparison (I2 = 0%, p = 0.82) (6).  Indicating improved 
survival based on early detection and treatment regardless of the treatment modality. 
Table 18. Hazard ratios comparing regional and relapse free survival based on neck nodal 
staging 
Study Neck stage Hazard ratio, p-value 
Kamal112 N1-N2a vs N2b-N3 HR = 0.32, p = 0.015 
Mizuta122 N1-N2a vs N2b-N3 HR = 0.28, p = 0.008 
HR = hazard ratio, HR < 1 survival favours lower neck stage, HR calculated as per Tierney et al.124 (Appendix III) 
 
Figure 10. Meta-analysis of regional and relapse free survival for two studies directly comparing 
low (N1 to N2a) and high (N2b to N3) neck (N) stage indicating survival benefit for lower neck 
stage at the beginning of treatment. 
 
3.4.3 Primary emergence 
Delayed emergence of a primary tumour (primary emergence [PE]) in a mucosal 
site is likely to be influenced by the primary or adjuvant radiation applied at the time of 
treatment.  All of the included studies except Mizuta et al.130 reported specific mucosal 
sites subjected to radiotherapy to cover potential occult tumour sites.  Mizuta et al.130 also 
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included a group with only neck dissection without any mucosal irradiation.  The 
remainder of the studies included nasopharynx and oropharynx in their radiation fields as 
potential occult primary sites.  Two studies126,131 only included ipsilateral oropharynx 
(Table 19) while the other eight studies reported bilateral mucosal site irradiation. 
However, there was no radiation laterality dependent relationship with PE, neck failure 
(NF) or distant metastasis (DM) (Figure 11).  Hypopharynx and laryngeal irradiation were 
patient dependent and based on whether the radiation oncologist had a strong suspicion 
of involvement of such mucosal sites based on risk factors such as smoking.  Most studies 
did not irradiate the larynx and the hypopharynx as routine practice.  Retropharyngeal 
nodes were also irradiated in almost all studies, with the exception of two studies88,126 that 
did not explicitly describe this region in their radiation fields.88,126   
 
Figure 11. Oropharyngeal irradiation laterality dependent changes to primary emergence (graph 
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Table 19. Mucosal irradiation sites for potential occult primary tumours 
Author N BOT T IO BO IL BL IH BH RPL 
Amsbaugh84 X X X  X  X  X NR 
Chen123 X X X X  NR NR X  X 
Demiroz118 X X X X  X  X  NR 
Frank119 X X X  X  X  X X 
Huo121 X X X  X   X  X 
Kamal112 X X X  X X  NR NR X 
Klem76 X X X  X  X  X X 
Lu6 X X X  X NR NR NR NR X 
Madani120 X X X  X NR NR X  X 
Mizuta122 NR NR NR NR NR NR NR NR NR NR 
N = nasopharynx, BOT = base of tongue, T = tonsil, IO = ipsilateral oropharynx, BO = bilateral oropharynx, IL = 
ipsilateral larynx, BL = bilateral larynx, IH = ipsilateral hypopharynx, BH = bilateral hypopharynx, RPL = 
retropharyngeal lymph nodes, NR = not reported, X = radiation field 
The overall PE following a minimum five-year follow-up period ranged from 0% 
to 11% (Table 20, Figure 12).  Mizuta et al.130 reported the highest rate (11%) of patients 
with a primary tumour emergence within a five-year period.  This result is likely due to 
the group in this study that was treated with pND alone, with no adjuvant radiotherapy.  
Four out of the ten studies reviewed here observed 0% PE.80,128,129,131  Those studies with 
no PE had variable treatment paradigms despite having achieved similar primary site 
control.  Huo et al.129 irradiated bilateral mucosal sites of patients that were deemed at 
risk of occult mucosal SCC and did not irradiate the mucosal sites of patients deemed to 
be at risk of cutaneous SCC.  Chen et al. treated all their patients with ipsilateral mucosal 
irradiation, while Klem et al.80 and Madani et al.128 treated bilateral mucosal sites with 
irradiation.  A clear relationship cannot be made between PE and treatment paradigms.  
Practically, a pND usually delays radiotherapy treatment to potential occult mucosal sites 
by approximately six to eight weeks.  However, this does not appear to have a clear 




Table 20. Treatment failures based on primary emergence, neck failure or distant metastasis 
Author 5-year PE (%) 5-year NF (%) 5-year DM (%) 
Amsbaugh84 4 (6%) 14 (21%) 10 (15%) 
Chen123 0 (0%) 2 (6%) 1 (3%) 
Demiroz118 2 (5%) 2 (5%) 8 (20%) 
Frank119 1 (2%) 3 (6%) 5 (10%) 
Huo121 0 (0%) 6 (10%) 6 (10%) 
Kamal112 14 (5%) 24 (9%) 16 (6%) 
Klem76 0 (0%) 3 (14%) 2 (10%) 
Lu6 1 (6%) 2 (11%) 2 (11%) 
Madani120 0 (0%) 1 (4%) 4 (17%) 
Mizuta122 9 (11%) 20 (25%) 10 (13%) 
Overall 31 (5%) 77 (12%) 64 (10%) 
PE = primary emergence, NF = neck failure, DM = distant metastasis 
 
 
Figure 12. Percentage of primary tumour emergence after five-year follow-up as a function of 
percentage of patients who had a primary neck dissection (graph A) and rate of patients who had 
a tonsillectomy (graph B) in each study. 
 
 
The rate of patients receiving a tongue base mucosectomy as part of the diagnostic 
process was reported as 0%, 10% and 100% for Huo et al.,129 Chen et al.131 and Amsbaugh 
et al.,88 respectively.  Their respective PE rates were 0%, 0% and 4%.  Therefore, a logical 
relationship cannot be made between tongue base mucosectomy alone and prevention of 
PE, whereby a patient selection paradigm based on risk factors such as in Huo et al.129 
may play a larger role influencing PE and determining who needs a tongue base 
mucosectomy.  The rate of tonsillectomies performed was reported in six 
studies6,88,120,126,129,131  and ranged from 41% to 100% (see  






































Table 18).  However, there was no clear relationship between the percentage of 
patients who had a tonsillectomy and PE (Figure 12B). 
3.4.4 Neck failure 
Neck failure is defined as a recurrence or residual disease in the neck occurring 
more than three months following the end of primary treatment (see Section 1.9).  Neck 
failure rates are likely related to: disease stage at the time of treatment, occult primary 
site and treatment modality utilised.  The overall neck failure rate after a minimum five-
year follow-up was 12% (range 4%-25%) (Table 20).  Again, the highest rate of patients 
with neck failure was noted in Mizuta et al.130 (25%), likely related to inadequate primary 
treatment, as mentioned earlier.  However, Amsbaugh et al.88 also reported a neck failure 
rate (21%) similar to Mizuta et al.,130 with vastly different treatment paradigms.  Mizuta 
et al.130 had a cohort of patients who were only treated with neck dissection of the affected 
side but did not have detailed reporting of irradiation sites for comparison, whereas the 
patients in Amsbaugh et al.88 had bilateral mucosa irradiation as well as primary or 
adjuvant radiotherapy to the affected neck as well as contralateral neck.  Both of these 
studies did not report on clinical target volumes or specific irradiation intensities for sites 
of interest.  The lowest rate of neck failures (4%) was observed by Madani et al.128 where 
the treatment paradigm included a bilateral mucosal irradiation as well as primary or 
adjuvant radiotherapy to bilateral necks.  The rate of neck dissections in each study is the 
only clear difference between Amsbaugh et al.88 (ND = 56%) and Madani et al.128 (ND = 
83%), both of which otherwise had similar radiation oncology treatment plans.  However, 
in contrast, Demiroz et al.126 reported a neck failure rate of 5% similar to Madani et al.128 
but only had 54% of their patients with primary neck dissections.  Therefore, a clear 
50 
 
relationship cannot be made between the rate of primary neck dissections performed and 
that of neck failure (Figure 13). 
 
Figure 13. Rate of neck failure after five-year follow-up as a function of rate of patients who had 
a primary neck dissection in each study. 
 
3.4.5 Distant metastasis 
The rate of patients with distant metastasis ranged from 3% to 20% (Table 20).  The 
study with the lowest reported rate of distant metastasis was Chen et al.131 and the study 
with the highest reported rate of distant metastasis was Demiroz et al126  Interestingly, 
both these studies only irradiated potential occult mucosal sites of the ipsilateral side with 
similar radiation intensities (Table 21); with the main interventional differences that 100% 
of patients in Chen et al.131 had a tonsillectomy compared to 41% in Demiroz et al.126  
Furthermore, 32% patients in Chen et al.131 had a primary neck dissection compared to 
54% in Demiroz et al.126  Since the rates of primary neck dissections in these two studies 
are similar, tonsillectomies may contribute to reducing distant metastasis.  However, the 
available data does not allow for the establishment of a causative relationship.  
Statistically, the percentage of patients with distant metastasis did not correlate well with 
rate of primary emergence, neck failure or neck dissections performed (p > 0.05).   
















Table 21. Clinical target volumes and respective radiation dosage 
Author  CTV1 (dose range) CTV2 (dose range) CTV3 (dose range) 
Amsbaugh84  NR NR NR 
Chen123 P 66-70Gy 60Gy (54-60) 60-66Gy 
 A 60-66Gy   
Demiroz118 P 70Gy 54Gy 56-59Gy 
 A 60Gy  54Gy 
Frank119 P 66Gy (60 – 72) 54Gy 54Gy 
 A 60Gy (60 – 70)   
Huo121  NR NR NR 
Kamal112 P 66Gy (63 – 72)  54Gy (50 – 66) 
 A 60Gy (60 – 66)   
Klem76 P 70Gy 54-60Gy 70Gy 
 A 60Gy (60- 70)  60Gy (60-70) 
Lu6 P 64-66Gy 60-64Gy 50-54Gy 
 A 60Gy 50-54Gy 60Gy 
Madani120 P 69Gy 56Gy 66Gy 
 A 62-66Gy   
Mizuta122  NR NR NR 
Overall 
(range) 
P 64 - 72Gy 50 - 64Gy 54 - 70Gy 
A 60 - 70Gy   
CTV = clinical target volumes, CTV1 = involved nodal basin, CTV2 = contralateral nodal basin, CTV3 = mucosa of 
potential occult primary sites, P = primary treatment, A = adjuvant treatment, Gy = gray, NR: = not reported 
3.5 Secondary outcomes 
3.5.1 Quality of life and treatment related toxicity 
The reporting of QoL markers and treatment related toxicities was poor overall 
(Table 22).  While most studies reported some aspects of treatment related toxicities, only 
Chen et al.131 used a validated instrument to assess QoL (Table 23).  Only Amsbaugh et 
al.88 reported treatment related toxicities stratified according to primary treatment 
modality (Table 23).  Surgery related toxicities or complications were not clearly reported 
by any of the studies included in this review. 
 Table 22. Reporting of quality of life or treatment related toxicity 
Author Year Toxicity and/or 
QoL reported 






Amsbaugh84 2017 Yes Yes No No 
Chen123 2017 Yes No Yes Yes 
Demiroz118 2014 No N/A N/A No 
Frank119 2010 Yes Yes No No 
Huo121 2018 No  N/A No 
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Author Year Toxicity and/or 
QoL reported 






Kamal112 2018 Yes  No No 
Klem76 2008 Yes  No No 
Lu6 2009 Yes  No No 
Madani120 2008 Yes  No No 
Mizuta122 2018 No  N/A No 
QoL = quality of life 
Based on Amsbaugh et al.,83 the overall toxicity of Grade III or higher in the pRT 
group was greater than that in the pND group (Table 23).  The largest contributor to this 
overall toxicity was dysphagia, that was higher (16.2%) in the pND group compared to 
the pRT group (13.8%).  Mucositis, a common toxicity related to radiotherapy, appears to 
be similar, irrespective of primary or adjuvant therapy dosage (13.8% compared to 13.5% 
respectively).  Xerostomia that is normally considered a common toxicity following 
radiotherapy.  However, rates of xerostomia in these studies were reported at very low 
rates and interestingly had a 0% reported rate following primary radiotherapy. 
Table 23: Comparative treatment related toxicity reporting 
Author Year Reported toxicity pND + aRT pRT 
Amsbaugh84 2017 Any toxicity 35.1% 41.4% 
  Xerostomia 2.7% 0% 
  Dermatitis 2.7% 10.3% 
  Dehydration 2.7% 10.3% 
  G-tube 8.1% 10.3% 
  Fibrosis 13.5% 3.4% 
  Mucositis 13.5% 13.8% 
  Dysphagia 16.2% 13.8% 
pND = primary neck dissection, aRT = adjuvant radiotherapy, pRT = primary radiotherapy, G-tube = gastrostomy 
tube dependence for more than six months post treatment 
In contrast to Amsbaugh et al.,83 studies with a higher rate of pND appeared to have 
a significantly higher percentage of patients with toxicity of Grade III or higher (Figure 
15, R2 = 0.9152, p = 0.0108), as this group of patients would also be treated with adjuvant 
radiotherapy with or without concurrent chemotherapy.  A cohort of these patients would 
receive a triple modality treatment, hence the likelihood of having worse toxicities.  The 




Figure 14. Percentage of patients with Grade III or higher toxicities as a function of percentage 
of patients who had a primary neck dissection in each study. 
 
  




























) R2 = 0.9152
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Table 24.  Number of patients with Grade III or higher acute or chronic toxicities 
Author Year Patients Grade III or higher toxicity Patients with toxicity (%) 
Amsbaugh88 2017 66 
Xerostomia, dermatitis, 
dehydration, G-tube, fibrosis, 
mucositis, dysphagia 
25 (38%) 
Frank127 2010 52 Dysphagia, G-tube 2 (4%) 
Kamal120 2018 260 G-tube, dysphagia, osteoradionecrosis 14 (5%) 
Klem80 2008 21 
Haematologic, skin toxicity, 
mucositis, dehydration, renal 
toxicity, pulmonary toxicity, 
infection, pain, constipation 
10 (48%) 
Lu6 2009 18 Mucositis, G-tube NR 
Madani128 2008 23 Mucositis, dysphagia, dermatitis, hoarse voice  19 (83%) 
Year = publication year; NR = not reported 
Table 25. GRADE Summary of Findings 
Outcomes 
Anticipated absolute effects* 














OS assessed with: 
Kaplan-Meier 
Survival Estimate 
follow up: range 2 
weeks to 176 
months 
2-year OS 
HR 0.86  







result in little or 
no difference to 
OS 
93 per 100 94 per 100 (90 – 97) 
5-year OS 




follow up: range 2 
weeks to 132 
months 
2-year RRFS HR 0.57  
(0.32 to 1.04)  













57 per 100 72 per 100 (55 to 83) 
4-year RRFS 
75 per 100 85 per 100 (74 to 91) 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group 
and the relative effect of the intervention (and its 95% CI). 
 
CI: Confidence interval; HR: Hazard Ratio 
 
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of 
the effect, but there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of 
the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different 
from the estimate of effect 
 
a = non-randomised study designs, retrospective data, no consistent diagnostic paradigm; b = patient demographics 
were similar; no significant statistical heterogeneity; c = wide confidence intervals; OS = overall survival, RRFS = 




4 CHAPTER 4: DISCUSSION 
4.1 Overview of findings 
The systematic analysis of ten studies comparing pND to pRT for the treatment of 
HNCUP found that the primary modality of treatment had no clinically relevant or 
statistically significant difference to OS (Section 3.4.1).  However, pND provided a better 
RRFS compared to pRT, although this is not statistically significant (Section 3.4.2).  The 
variations in regional failure is likely multifactorial.  However, the studies reviewed here 
did not provide adequate data to investigate causative relationships.  Local practices such 
as how often and thoroughly these patients are followed up after their treatment is likely 
to affect regional failure pick up rate.  The majority of studies reported a clinically 
acceptable PE under 6% after a five-year follow-up. The one study reporting more than 
10% PE130 treated their patients with only neck dissection (Section 3.4.3); this is not the 
recommended treatment modality in current guidelines.134  The number of neck failures 
had no clear relationship with primary treatment modality or radiation treatment protocols 
(Section 3.4.4).  The number of distant metastases had a clear linear relationship with the 
pND conducted in each study, where the study with the highest rate of pND had the 
highest incidence of distant metastasis (Section 3.4.5).  Treatment related toxicities and 
patient reported QoL were poorly described in the literature analysed.  This may be in 
part due to lack of validated tools to evaluate surgical complications and the toxicities 
related to radiotherapy do not occur following surgery to allow for direct comparison.  
Therefore, meaningful inferences from toxicity or QoL in relation to treatment decision 
making is difficult.  Analysis of diagnostic criteria in each study indicated a large variation 
in treatment paradigms from study to study, generating largely inconsistent survival 
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outcome measures.  Overall, there is no clear evidence to favour pND or pRT for the 
treatment of HNCUP.  However, the certainty of these results is rated low (Table 25). 
Advanced surgical techniques with improved access to parts of the anatomy that are 
difficult to locate, with reduced treatment related morbidity, provide an attractive 
treatment option for patients.  However, the reduced toxicity of novel radiotherapy 
techniques has also improved patient QoL while maintaining treatment efficacy.  In 
HNCUP, the optimum treatment modality to pursue continues to be a dilemma due to the 
poor evidence available to inform decision making.  While non-invasive techniques such 
as FDG-PET scanning has markedly improved the detection of primary cancers, the 
patients left with true unknown primary diseases appear to receive more toxic treatments 
and, ultimately, poorer outcomes.135  Due to the complex anatomy and myriad of potential 
primary sites within the head and neck region, risk stratification and the subsequent 
applied treatment modality has not always been the best choice for the individual patient.  
The relatively low incidence of true unknown primary HNSCC (three per 100,000 cases 
per year)9 is also problematic for evidence gathering, as any high quality study would 
require a significant duration to recruit an adequate number of patients for statistical 
power, hence the lack of randomised prospective studies. 
The previous meta-analysis by Liu et al.9 on a similar topic had reported greater 
five-year OS and DFS when surgery was combined with RT compared to RT alone.  This 
is in contrast to our findings of no difference between treatment modality and OS.  Our 
study did not include any of the individual studies pooled by Liu et al.9 as they pre-dated 
the search window for this systematic review.  Also Liu et al.9 included studies pre-dating 
the use of FDG-PET scanning as a routine in the diagnostic process of HNCUP.  Therefore, 
it is likely that some of the included studies would contain ‘non-true’ HNCUP participants 
57 
 
(poorly sensitive diagnostic paradigm).  Due to high smoking rates in the past, older 
studies are more likely to have patients with HNSCC that are not virally (HPV) mediated, 
therefore, the observed response to pRT is likely to be less effective than more recent 
studies.   Current review included up to 20% (Table 10) HPV positive patients with good 
response to pRT.136  This is not implying pRT is superior to pND in HPV positive HNSCC 
patients.  They also reported less primary tumour emergence in patients treated with RT 
to both the affected neck and occult mucosal sites.  However, we did not see such a clear 
relationship between RT protocol and PE, mainly because we did not have studies directly 
comparing neck only RT to neck and mucosal RT as compared by Liu et al.9   
Another systematic review by Balaker et al.10 analysing studies from 1998 to 2010 
reported that survival outcomes were largely dependent on the disease stage at the time 
of diagnosis and treatment modality had no influence on OS.  These authors did not 
conduct a pooled meta-analysis as a part of their review.  Balaker et al.10 included one 
study6 that was in common with our review but the rest of the studies pre-dated our search 
window.  Interestingly, there was a large difference between minimum and maximum 
five-year OS noted in their review: 25% (study from 2006137) and 79% (study from 
2007138), respectively, compared to our review where minimum and maximum five-year 
OS was 64% (study from 20096) and 85% (study from 2008120), respectively.  There 
appears to be a publication year dependent improvement in five-year OS,  likely related 
to improved prognosis from higher prevalence of HPV related HNSCC as well as 
improved identification of small tumours with FDG-PET139 and robotic techniques.74,79  
While the results of this review echo our findings, the study participants were included 
when FDG-PET was not routinely used to identify an occult primary site and at a time 
when HPV rates were not a significant factor affecting overall prognosis.  These 
58 
 
confounding factors reduce the confidence in the overall result of their review. As 
mentioned, FDG-PET scan is paramount for the identification of ‘true’ HNCUP.  This is 
recommended by USA134 and United Kingdom140 HNCUP treatment guidelines. 
There appears to be a conflict between protocolised, institution-based treatment 
paradigms and the novel approach of individualised patient care.  The lack of standardised 
treatment protocols in the past decade appears to have hindered the development of 
individualised care plans.  Utilisation of patient risk profiles and a patient dependent 
diagnostic paradigm may yield improved identification of an occult primary and better 
treatment outcomes for this group of patients. 
4.2 Limitations of the review 
Despite rigorous searching, we were unable to identify prospective randomised 
studies that directly compared the two primary modalities of treatment.  Hence, there are 
significant confounding factors considered in this analysis that are inherent to 
retrospective datasets.  The study selection and data extraction were performed by only 
one reviewer that adds to the risk of error.  Furthermore, meta-analysis conducted here is 
based on estimated data interpolated from published material.   
4.3 Implications for clinical practice 
The results of this systematic review do not favour either primary surgery or 
primary radiotherapy as the superior treatment modality and neither offers a clear OS 
benefit.  Therefore, both treatment options should be put forward for shared decision 
making with the patient.  However, due to the nature of studies included in this review, 
the certainty of the above result is low. 
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However, it appears that individualised treatment plans based on risk factors could 
maintain treatment effectiveness while reducing morbidity, as demonstrated in the study 
by Huo et al.129  Using patient history and examination to determine if the unknown 
primary SCC is from a skin or a mucosal source could determine which primary treatment 
modality is offered, hence, avoiding mucosal irradiation to patients presumed to have a 
occult cutaneous malignancy.  
4.4 Consideration for future clinical practice 
If a patient is presumed to have an occult mucosal primary cancer (due to heavy 
smoking history, heavy alcohol intake, previous oral/oropharyngeal lesions with 
dysplasia, lack of cutaneous SCC risk factors) that has metastasised to the neck, then pRT 
to the potential mucosal sites as well as the affected neck should be considered their 
primary treatment option.  However, there is no clear evidence to guide when this group 
of patients should have a neck dissection.  It could be argued that higher nodal disease 
(N2b and above) would benefit from surgical disease clearance followed by adjuvant 
radiotherapy.  However, a pND would delay radiotherapy treatment to occult mucosal 
sites, potentially increasing the risk of PE and DM.  However, the data analysed in this 
systematic review, regardless of the primary treatment modality, suggests that the PE rate 
was fairly constant at 5%.  This patient group should receive a FDG-PET scan, bilateral 
tonsillectomy and a tongue base mucosectomy (or at least directed biopsies) during the 
diagnostic phase. 
On the contrary, if a patient is presumed to have an occult skin malignancy 
(previous skin SCC, Fitzpatrick skin type 1, actinic skin, parotid involvement) that has 
metastasised to the neck, they should be treated with a pND and adjuvant radiotherapy.  
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Also, these patients should be spared from radiotherapy to occult mucosal sites, thus 
reducing radiotherapy related morbidity.  A superficial parotidectomy in the absence of 
gross parotid disease should also be considered in a presumed cutaneous primary tumour 
due to the first echelon nodes from the head and facial skin draining to intra-parotid lymph 
nodes.  This group of patients should not have a diagnostic tonsillectomy or a tongue base 
mucosectomy. 
However, the dilemma still exists for patients with no clear history favouring either 
primary site or the p16 status of nodal tissue.  Given the p16 marker is positive in 
approximately 30% of cutaneous SCCs, this marker cannot be used as a method of 
determining the likely occult primary site.  This patient group should be offered primary 
surgery with adjuvant radiotherapy as well as irradiation to occult mucosal sites.  These 
patients should also receive a diagnostic bilateral tonsillectomy and tongue base 
mucosectomy (or equivalent).  If p16 status is negative, primary surgery followed by 
adjuvant radiotherapy should be recommended. 
Concurrent chemotherapy in combination with radiotherapy should be determined 
by histological or radiological identification of extra-capsular spread as detailed in known 
primary guidelines.134  However, primary radiotherapy patients should receive a 
combined form of chemotherapy as this has shown to increase survival in known primary 
HNSCCs.141 
4.5 Implications for research 
This review provides the foundation for future clinical research for a direct 
comparison of primary modality of treatment for HNCUP.  As we did not identify a 
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significant difference in survival outcomes, ethically, it would be appropriate to 
randomise patients to either primary treatment modality in a trial setting.  However, due 
to the relatively similar survival rates between treatment modalities, a large sample size 
would be required to adequately power a clinical trial.  Also, HNCUP with a very low 
incidence, recruitment of large number of patients would be impractical.  Therefore, large, 
well designed retrospective studies are likely to provide valuable data for clinical decision 
making.  Clinical registries with appropriate data collection to calculate overall as well 
disease specific outcomes becomes an important component of such research. 
Overall, there was a lack of high-quality evidence to confidently inform clinical 
decision making.  There were no published or unpublished RCTs on the topic.  Future 
studies should report on clinically relevant survival end points that are consistent to allow 
for appropriate data synthesis.  Kaplan-Meier plots should always report the at-risk 
number of participants at each time interval to allow for accurate pooling of data for 
meaningful clinical decision making.   
The risk factors associated with HNSCC are many and variable amongst patients.  
Therefore, stratified data reporting based on patient risk factors could also guide clinical 
decision making in the future.  p16 status should be stratified in future HNCUP data 
reporting as this continues to be a dilemma in decision making.  Further high-quality data 
is required to identify the best treatment modality or a combination of modalities for the 
treatment of patients with p16 positive neck nodal metastasis with presumed mucosal or 
cutaneous origin.  We propose stratification of patient survival data according to p16 





There were no clinically or statistically significant survival difference between 
primary surgery or primary radiotherapy for the treatment of unknown primary head and 
neck squamous cell carcinoma.  While primary neck dissection appears to benefit 
locoregional control of disease, this was not statistically significant.  Higher stage of neck 
disease results in poorer overall survival, regardless of the primary treatment modality.  





1. Motz K, Qualliotine JR, Rettig E, Richmon JD, Eisele DW, Fakhry C. Changes in 
Unknown Primary Squamous Cell Carcinoma of the Head and Neck at Initial Presentation 
in the Era of Human Papillomavirus. JAMA Otolaryngol Head Neck Surg. 2016; 
142(3):223-8. 
2. Strojan P, Ferlito A, Medina JE, Woolgar JA, Rinaldo A, Robbins KT, et al. 
Contemporary management of lymph node metastases from an unknown primary to the 
neck: I. A review of diagnostic approaches. Head Neck. 2013; 35(1):123-32. 
3. Karapolat I, Kumanlioglu K. Impact of FDG-PET/CT for the Detection of Unknown 
Primary Tumours in Patients with Cervical Lymph Node Metastases. Mol Imaging 
Radionucl Ther. 2012; 21(2):63-8. 
4. Amsbaugh MJ, Yusuf M, Cash E, Silverman C, Wilson E, Bumpous J, et al. Distribution 
of Cervical Lymph Node Metastases From Squamous Cell Carcinoma of the Oropharynx 
in the Era of Risk Stratification Using Human Papillomavirus and Smoking Status. Int J 
Radiat Oncol Biol Phys. 2016; 96(2):349-53. 
5. Hatten KM, O'Malley BW, Jr., Bur AM, Patel MR, Rassekh CH, Newman JG, et al. 
Transoral Robotic Surgery-Assisted Endoscopy With Primary Site Detection and 
Treatment in Occult Mucosal Primaries. JAMA Otolaryngol Head Neck Surg. 2017; 
143(3):267-73. 
6. Lu H, Yao M, Tan H. Unknown primary head and neck cancer treated with intensity-
modulated radiation therapy: to what extent the volume should be irradiated. Oral Oncol. 
2009; 45(6):474-9. 
7. Studer G, Huber GF, Holz E, Glanzmann C. Less may be more: nodal treatment in neck 
positive head neck cancer patients. Eur Arch Otorhinolaryngol. 2016; 273(6):1549-56. 
8. Maquieira R, Haerle SK, Huber GF, Soltermann A, Haile SR, Stoeckli SJ, et al. No 
benefit for regional control and survival by planned neck dissection in primary irradiated 
oropharyngeal cancer irrespective of p16 expression. Eur Arch Otorhinolaryngol. 2016; 
273(7):1841-8. 
9. Liu X, Li D, Li N, Zhu X. Optimization of radiotherapy for neck carcinoma metastasis 
from unknown primary sites: a meta-analysis. Oncotarget. 2016; 7(48):78736-46. 
10. Balaker AE, Abemayor E, Elashoff D, St John MA. Cancer of unknown primary: does 
treatment modality make a difference? Laryngoscope. 2012; 122(6):1279-82. 
11. Licitra L, Locati LD, Bossi P, Cantu G. Head and neck tumors other than squamous 
cell carcinoma. Curr Opin Oncol. 2004; 16(3):236-41. 
12. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide 
burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12):2893-917. 
64 
 
13. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008; 
371(9625):1695-709. 
14. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct risk 
factor profiles for human papillomavirus type 16-positive and human papillomavirus type 
16-negative head and neck cancers. J Natl Cancer Inst. 2008; 100(6):407-20. 
15. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case–
Control Study of Human Papillomavirus and Oropharyngeal Cancer. N Engl J Med. 2007; 
356(19):1944-56. 
16. Robbins KT, Clayman G, Levine P, Medina JE, Sessions R, Shaha A, et al. Neck 
Dissection Classification Update. Arch Otolaryngol Head Neck Surg. 2002; 128. 
17. Kulzer MH, Branstetter BFt. Chapter 1 Neck Anatomy, Imaging-Based Level Nodal 
Classification and Impact of Primary Tumor Site on Patterns of Nodal Metastasis. Semin 
Ultrasound CT MR. 2017; 38(5):454-65. 
18. Gaillard F. Lymph node levels. Radiopedia.org; 2019 [cited 2019 24/07/2019]. 
Available from: https://radiopaedia.org/cases/lymph-node-levels 
19. Rouvière H. Anatomie des lymphatiques de l'homme. Masson et Cie, editeurs; 1932. 
20. Shah JP, Strong E, Spiro RH, Vikram B. Surgical grand rounds. Neck dissection: 
current status and future possibilities. Clin Bull. 1981; 11(1):25-33. 
21. Som PM, Curtin HD, Mancuso AA. An imaging-based classification for the cervical 
nodes designed as an adjunct to recent clinically based nodal classifications. Arch 
Otolaryngol Head Neck Surg. 1999; 125(4):388-96. 
22. Som PM, Curtin HD, Mancuso AA. Imaging-based nodal classification for evaluation 
of neck metastatic adenopathy. AJR Am J Roentgenol. 2000; 174(3):837-44. 
23. Robbins KT, Clayman G, Levine PA, Medina J, Sessions R, Shaha A, et al. Neck 
dissection classification update: revisions proposed by the American Head and Neck 
Society and the American Academy of Otolaryngology-Head and Neck Surgery. Arch 
Otolaryngol Head Neck Surg. 2002; 128(7):751-8. 
24. Robbins KT, Shaha AR, Medina JE, Califano JA, Wolf GT, Ferlito A, et al. Consensus 
statement on the classification and terminology of neck dissection. Arch Otolaryngol 
Head Neck Surg. 2008; 134(5):536-8. 
25. Stepnick D, Gilpin D. Head and neck cancer: an overview. Semin Plast Surg. 2010; 
24(2):107-16. 
26. O'Brien CJ, McNeil EB, McMahon JD, Pathak I, Lauer CS, Jackson MA. Significance 
of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous 
squamous carcinoma of the parotid gland. Head Neck. 2002; 24(5):417-22. 
65 
 
27. Joseph MG, Zulueta WP, Kennedy PJ. Squamous cell carcinoma of the skin of the 
trunk and limbs: the incidence of metastases and their outcome. Aust N Z J Surg. 1992; 
62(9):697-701. 
28. Vauterin TJ, Veness MJ, Morgan GJ, Poulsen MG, O'Brien CJ. Patterns of lymph node 
spread of cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2006; 
28(9):785-91. 
29. Cicero G, D'Angelo T, Racchiusa S, Salamone I, Visalli C, Bottari A, et al. Cross-
sectional Imaging of Parotid Gland Nodules: A Brief Practical Guide. J Clin Imaging Sci. 
2018; 8:14. 
30. Ying YL, Johnson JT, Myers EN. Squamous cell carcinoma of the parotid gland. Head 
Neck. 2006; 28(7):626-32. 
31. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The 
Mutational Landscape of Head and Neck Squamous Cell Carcinoma. Science. 2011; 
333(6046):1157-60. 
32. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck 
cancer. Nat Rev Cancer. 2011; 11(1):9-22. 
33. Braakhuis BJ, Leemans CR, Brakenhoff RH. A genetic progression model of oral 
cancer: current evidence and clinical implications. J Oral Pathol Med. 2004; 33(6):317-
22. 
34. Rothenberg SM, Ellisen LW. The molecular pathogenesis of head and neck squamous 
cell carcinoma. J Clin Invest. 2012; 122(6):1951-7. 
35. Nees M, Homann N, Discher H, Andl T, Enders C, Herold-Mende C, et al. Expression 
of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a 
possible molecular basis for the development of multiple tumors. Cancer Res. 1993; 
53(18):4189-96. 
36. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, et al. 
TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J 
Med. 2007; 357(25):2552-61. 
37. Ai L, Stephenson KK, Ling W, Zuo C, Mukunyadzi P, Suen JY, et al. The p16 
(CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: a 
promoter methylation and protein expression study in 100 cases. Mod Pathol. 2003; 
16(9):944-50. 
38. Sun W, Gaykalova DA, Ochs MF, Mambo E, Arnaoutakis D, Liu Y, et al. Activation 
of the NOTCH pathway in head and neck cancer. Cancer Res. 2014; 74(4):1091-104. 
39. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome 
sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in 
NOTCH1. Science. 2011; 333(6046):1154-7. 
66 
 
40. Henken FE, Banerjee NS, Snijders PJ, Meijer CJ, De-Castro Arce J, Rosl F, et al. 
PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in 
vitro. Mol Cancer. 2011; 10:71. 
41. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003; 
16(1):1-17. 
42. Pyeon D, Newton MA, Lambert PF, den Boon JA, Sengupta S, Marsit CJ, et al. 
Fundamental differences in cell cycle deregulation in human papillomavirus-positive and 
human papillomavirus-negative head/neck and cervical cancers. Cancer Res. 2007; 
67(10):4605-19. 
43. Hebner CM, Laimins LA. Human papillomaviruses: basic mechanisms of 
pathogenesis and oncogenicity. Rev Med Virol. 2006; 16(2):83-97. 
44. Kim KY, Zhang X, Cha IH. Identification of human papillomavirus status specific 
biomarker in head and neck cancer. Head Neck. 2015; 37(9):1310-8. 
45. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct 
epidemiologic, clinical, and molecular entity. Semin Oncol. 2004; 31(6):744-54. 
46. Schache AG, Liloglou T, Risk JM, Jones TM, Ma XJ, Wang H, et al. Validation of a 
novel diagnostic standard in HPV-positive oropharyngeal squamous cell carcinoma. Br J 
Cancer. 2013; 108(6):1332-9. 
47. Dixon PR, Au M, Hosni A, Perez-Ordonez B, Weinreb I, Xu W, et al. Impact of p16 
expression, nodal status, and smoking on oncologic outcomes of patients with head and 
neck unknown primary squamous cell carcinoma. Head Neck. 2016; 38(9):1347-53. 
48. Accardi R, Gheit T. Cutaneous HPV and skin cancer. Presse Med. 2014; 43(12 Pt 
2):e435-43. 
49. Hampras SS, Reed RA, Bezalel S, Cameron M, Cherpelis B, Fenske N, et al. 
Cutaneous Human Papillomavirus Infection and Development of Subsequent Squamous 
Cell Carcinoma of the Skin. J Skin Cancer. 2016; 2016:1368103. 
50. Wang J, Aldabagh B, Yu J, Arron ST. Role of human papillomavirus in cutaneous 
squamous cell carcinoma: a meta-analysis. J Am Acad Dermatol. 2014; 70(4):621-9. 
51. Wells LA, Junor EJ, Conn B, Pattle S, Cuschieri K. Population-based p16 and HPV 
positivity rates in oropharyngeal cancer in Southeast Scotland. J Clin Pathol. 2015; 
68(10):849-52. 
52. Lassen P, Primdahl H, Johansen J, Kristensen CA, Andersen E, Andersen LJ, et al. 
Impact of HPV-associated p16-expression on radiotherapy outcome in advanced 
oropharynx and non-oropharynx cancer. Radiother Oncol. 2014; 113(3):310-6. 
53. Gronhoj Larsen C, Gyldenlove M, Jensen DH, Therkildsen MH, Kiss K, Norrild B, 
et al. Correlation between human papillomavirus and p16 overexpression in 
oropharyngeal tumours: a systematic review. Br J Cancer. 2014; 110(6):1587-94. 
67 
 
54. Husain N, Neyaz A. Human papillomavirus associated head and neck squamous cell 
carcinoma: Controversies and new concepts. J Oral Biol Craniofac Res. 2017; 7(3):198-
205. 
55. Coordes A, Lenz K, Qian X, Lenarz M, Kaufmann AM, Albers AE. Meta-analysis of 
survival in patients with HNSCC discriminates risk depending on combined HPV and 
p16 status. Eur Arch Otorhinolaryngol. 2016; 273(8):2157-69. 
56. Lewis JS, Jr., Beadle B, Bishop JA, Chernock RD, Colasacco C, Lacchetti C, et al. 
Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the 
College of American Pathologists. Arch Pathol Lab Med. 2018; 142(5):559-97. 
57. Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. 
Head and Neck cancers-major changes in the American Joint Committee on cancer eighth 
edition cancer staging manual. CA Cancer J Clin. 2017; 67(2):122-37. 
58. Kim KY, Lewis JS, Jr., Chen Z. Current status of clinical testing for human 
papillomavirus in oropharyngeal squamous cell carcinoma. J Pathol Clin Res. 2018; 
4(4):213-26. 
59. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of 
the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 
17(6):1471-4. 
60. Huang SH, O'Sullivan B. Overview of the 8th Edition TNM Classification for Head 
and Neck Cancer. Curr Treat Options Oncol. 2017; 18(7):40. 
61. Weber A, Schmoz S, Bootz F. CUP (carcinoma of unknown primary) syndrome in 
head and neck: clinic, diagnostic, and therapy. Onkologie. 2001; 24(1):38-43. 
62. Rudmik L, Lau HY, Matthews TW, Bosch JD, Kloiber R, Molnar CP, et al. Clinical 
utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an 
unknown primary: a prospective clinical trial. Head Neck. 2011; 33(7):935-40. 
63. Cianchetti M, Mancuso AA, Amdur RJ, Werning JW, Kirwan J, Morris CG, et al. 
Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes 
from an unknown head and neck primary site. Laryngoscope. 2009; 119(12):2348-54. 
64. Berta E, Atallah I, Reyt E, Boyer E, Karkas A, Righini CA. The role of tonsillectomy 
in the initial diagnostic work-up of head and neck squamous cell carcinoma of unknown 
primary. Eur Ann Otorhinolaryngol Head Neck Dis. 2014; 131(5):305-8. 
65. Mehta V, Johnson P, Tassler A, Kim S, Ferris RL, Nance M, et al. A new paradigm for 
the diagnosis and management of unknown primary tumors of the head and neck: a role 
for transoral robotic surgery. Laryngoscope. 2013; 123(1):146-51. 
66. Cheol Park G, Roh JL, Cho KJ, Seung Kim J, Hyeon Jin M, Choi SH, et al. 18 F-FDG 
PET/CT vs. human papillomavirus, p16 and Epstein-Barr virus detection in cervical 




67. Dale E, Moan JM, Osnes TA, Bogsrud TV. Cervical lymph node metastases of 
squamous cell carcinoma of unknown origin: the diagnostic value of FDG PET/CT and 
clinical outcome. Eur Arch Otorhinolaryngol. 2017; 274(2):1015-9. 
68. Hung YH, Liu SA, Wang CC, Wang CP, Jiang RS, Wu SH. Treatment outcomes of 
unknown primary squamous cell carcinoma of the head and neck. PLoS One. 2018; 
13(10):e0205365. 
69. LaVigne AW, Margalit DN, Rawal B, Puzanov M, Annino DJ, Goguen LA, et al. 
IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes 
and improved toxicity with decreased mucosal dose and larynx sparing. Head Neck. 2019; 
41(4):959-66. 
70. Lou J, Wang S, Wang K, Chen C, Zhao J, Guo L. Squamous cell carcinoma of cervical 
lymph nodes from an unknown primary site: The impact of neck dissection. J Cancer Res 
Ther. 2015; 11 Suppl 2:C161-7. 
71. Dragan AD, Nixon IJ, Guerrero-Urbano MT, Oakley R, Jeannon JP, Simo R. Selective 
neck dissection as a therapeutic option in management of squamous cell carcinoma of 
unknown primary. Eur Arch Otorhinolaryngol. 2014; 271(5):1249-56. 
72. Wilson YL, Merer DM, Moscatello AL. Comparison of three common tonsillectomy 
techniques: a prospective randomized, double-blinded clinical study. Laryngoscope. 
2009; 119(1):162-70. 
73. Gallagher TQ, Wilcox L, McGuire E, Derkay CS. Analyzing factors associated with 
major complications after adenotonsillectomy in 4776 patients: comparing three 
tonsillectomy techniques. Otolaryngol Head Neck Surg. 2010; 142(6):886-92. 
74. Krishnan S, Connell J, Ofo E. Transoral robotic surgery base of tongue mucosectomy 
for head and neck cancer of unknown primary. ANZ J Surg. 2017; 87(12):E281-E4. 
75. Winter SC, Ofo E, Meikle D, Silva P, Fraser L, O'Hara J, et al. Trans-oral robotic 
assisted tongue base mucosectomy for investigation of cancer of unknown primary in the 
head and neck region. The UK experience. Clin Otolaryngol. 2017; 42(6):1247-51. 
76. Patel SA, Magnuson JS, Holsinger FC, Karni RJ, Richmon JD, Gross ND, et al. 
Robotic surgery for primary head and neck squamous cell carcinoma of unknown site. 
JAMA Otolaryngol Head Neck Surg. 2013; 139(11):1203-11. 
77. Byrd JK, Smith KJ, de Almeida JR, Albergotti WG, Davis KS, Kim SW, et al. 
Transoral Robotic Surgery and the Unknown Primary: A Cost-Effectiveness Analysis. 
Otolaryngol Head Neck Surg. 2014; 150(6):976-82. 
78. Fu TS, Foreman A, Goldstein DP, de Almeida JR. The role of transoral robotic surgery, 
transoral laser microsurgery, and lingual tonsillectomy in the identification of head and 
neck squamous cell carcinoma of unknown primary origin: a systematic review. J 
Otolaryngol Head Neck Surg. 2016; 45(1):28. 
79. Meccariello G, Cammaroto G, Ofo E, Calpona S, Parisi E, D'Agostino G, et al. The 
emerging role of trans-oral robotic surgery for the detection of the primary tumour site in 
69 
 
patients with head-neck unknown primary cancers: A meta-analysis. Auris Nasus Larynx. 
2019. 
80. Klem ML, Mechalakos JG, Wolden SL, Zelefsky MJ, Singh B, Kraus D, et al. 
Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity 
and preliminary efficacy. Int J Radiat Oncol Biol Phys. 2008; 70(4):1100-7. 
81. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. 
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck 
cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. The Lancet 
Oncology. 2011; 12(2):127-36. 
82. Sher DJ, Balboni TA, Haddad RI, Norris CM, Jr., Posner MR, Wirth LJ, et al. Efficacy 
and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown 
primary of head and neck. Int J Radiat Oncol Biol Phys. 2011; 80(5):1405-11. 
83. Fang FM, Chuang HC, Chou SY, Huang TL, Wang CJ, Lin YT, et al. The Therapeutic 
Benefit of Radical Resection for T4b Oral Cavity Squamous Cell Carcinoma with Partial 
or Complete Response After Radical Chemo-Intensity-Modulated Radiotherapy (IMRT). 
Ann Surg Oncol. 2016; 23(Suppl 5):866-73. 
84. Argiris A, Smith SM, Stenson K, Mittal BB, Pelzer HJ, Kies MS, et al. Concurrent 
chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an 
occult primary. Ann Oncol. 2003; 14(8):1306-11. 
85. de Braud F, Heilbrun LK, Ahmed K, Sakr W, Ensley JF, Kish JA, et al. Metastatic 
squamous cell carcinoma of an unknown primary localized to the neck. Advantages of an 
aggressive treatment. Cancer. 1989; 64(2):510-5. 
86. Chen AM, Farwell DG, Lau DH, Li BQ, Luu Q, Donald PJ. Radiation therapy in the 
management of head-and-neck cancer of unknown primary origin: how does the addition 
of concurrent chemotherapy affect the therapeutic ratio? Int J Radiat Oncol Biol Phys. 
2011; 81(2):346-52. 
87. Punt CJA, Buyse M, Köhne C-H, Hohenberger P, Labianca R, Schmoll HJ, et al. 
Endpoints in Adjuvant Treatment Trials: A Systematic Review of the Literature in Colon 
Cancer and Proposed Definitions for Future Trials. J Natl Cancer Inst. 2007; 99(13):998-
1003. 
88. Amsbaugh MJ, Yusuf M, Gaskins J, Silverman C, Potts K, Bumpous J, et al. Neck 
dissection for unknown cancer of the head and neck in the era of chemoradiation. Am J 
Otolaryngol. 2017; 38(5):588-92. 
89. Givens DJ, Karnell LH, Gupta AK, Clamon GH, Pagedar NA, Chang KE, et al. 
Adverse events associated with concurrent chemoradiation therapy in patients with head 
and neck cancer. Arch Otolaryngol Head Neck Surg. 2009; 135(12):1209-17. 
90. Heutte N, Plisson L, Lange M, Prevost V, Babin E. Quality of life tools in head and 
neck oncology. Eur Ann Otorhinolaryngol Head Neck Dis. 2014; 131(1):33-47. 
70 
 
91. Felce D, Perry J. Quality of life: its definition and measurement. Res Dev Disabil. 
1995; 16(1):51-74. 
92. Short SO, Kaplan JN, Laramore GE, Cummings CW. Shoulder pain and function after 
neck dissection with or without preservation of the spinal accessory nerve. Am J Surg. 
1984; 148(4):478-82. 
93. Fennessy BG, Harney M, O'Sullivan MJ, Timon C. Antimicrobial prophylaxis in 
otorhinolaryngology/head and neck surgery. Clin Otolaryngol. 2007; 32(3):204-7. 
94. Goguen LA, Chapuy CI, Li Y, Zhao SD, Annino DJ. Neck dissection after 
chemoradiotherapy: timing and complications. Arch Otolaryngol Head Neck Surg. 2010; 
136(11):1071-7. 
95. Kerawala CJ, Heliotos M. Prevention of complications in neck dissection. Head Neck 
Oncol. 2009; 1:35. 
96. Givens DJ, Karnell Lh Fau - Gupta AK, Gupta Ak Fau - Clamon GH, Clamon Gh Fau 
- Pagedar NA, Pagedar Na Fau - Chang KE, Chang Ke Fau - Van Daele DJ, et al. Adverse 
events associated with concurrent chemoradiation therapy in patients with head and neck 
cancer. (1538-361X (Electronic)). 
97. Trotti A, Pajak TF, Gwede CK, Paulus R, Cooper J, Forastiere A, et al. TAME: 
development of a new method for summarising adverse events of cancer treatment by the 
Radiation Therapy Oncology Group. Lancet Oncol. 2007; 8(7):613-24. 
98. Jiang N, Zhang LJ, Li LY, Zhao Y, Eisele DW. Risk factors for late dysphagia after 
(chemo)radiotherapy for head and neck cancer: A systematic methodological review. 
Head Neck. 2016; 38(5):792-800. 
99. Bressan V, Stevanin S, Bianchi M, Aleo G, Bagnasco A, Sasso L. The effects of 
swallowing disorders, dysgeusia, oral mucositis and xerostomia on nutritional status, oral 
intake and weight loss in head and neck cancer patients: A systematic review. Cancer 
Treat Rev. 2016; 45:105-19. 
100. Heijnen BJ, Speyer R, Kertscher B, Cordier R, Koetsenruijter KW, Swan K, et al. 
Dysphagia, Speech, Voice, and Trismus following Radiotherapy and/or Chemotherapy in 
Patients with Head and Neck Carcinoma: Review of the Literature. Biomed Res Int. 2016; 
2016:6086894. 
101. Lazarus CL. Effects of chemoradiotherapy on voice and swallowing. Curr Opin 
Otolaryngol Head Neck Surg. 2009; 17(3):172-8. 
102. Rogers SN, Ahad SA, Murphy AP. A structured review and theme analysis of papers 
published on 'quality of life' in head and neck cancer: 2000-2005. Oral Oncol. 2007; 
43(9):843-68. 
103. Klein J, Livergant J, Ringash J. Health related quality of life in head and neck cancer 
treated with radiation therapy with or without chemotherapy: a systematic review. Oral 
Oncol. 2014; 50(4):254-62. 
71 
 
104. Chen AY, Frankowski R, Bishop-Leone J, Hebert T, Leyk S, Lewin J, et al. The 
development and validation of a dysphagia-specific quality-of-life questionnaire for 
patients with head and neck cancer: the M. D. Anderson dysphagia inventory. Arch 
Otolaryngol Head Neck Surg. 2001; 127(7):870-6. 
105. Crary MA, Mann GD, Groher ME. Initial psychometric assessment of a functional 
oral intake scale for dysphagia in stroke patients. Arch Phys Med Rehabil. 2005; 
86(8):1516-20. 
106. Bogaardt HC, Hakkesteegt MM, Grolman W, Lindeboom R. Validation of the voice 
handicap index using Rasch analysis. J Voice. 2007; 21(3):337-44. 
107. Rosen CA, Lee AS, Osborne J, Zullo T, Murry T. Development and validation of the 
voice handicap index-10. Laryngoscope. 2004; 114(9):1549-56. 
108. Hogikyan ND, Sethuraman G. Validation of an instrument to measure voice-related 
quality of life (V- RQOL). Journal of Voice. 1999; 13(4):557-69. 
109. Rosen CA, Lee As Fau - Osborne J, Osborne J Fau - Zullo T, Zullo T Fau - Murry T, 
Murry T. Development and validation of the voice handicap index-10. (0023-852X 
(Print)). 
110. Bogaardt HC, Hakkesteegt Mm Fau - Grolman W, Grolman W Fau - Lindeboom R, 
Lindeboom R. Validation of the voice handicap index using Rasch analysis. (0892-1997 
(Print)). 
111. The periodic health examination. Canadian Task Force on the Periodic Health 
Examination. Can Med Assoc J. 1979; 121(9):1193-254. 
112. Sackett DL. Rules of evidence and clinical recommendations on the use of 
antithrombotic agents. Chest. 1989; 95(2 Suppl):2S-4S. 
113. Editors PLM. Best practice in systematic reviews: the importance of protocols and 
registration. PLoS Med. 2011; 8(2):e1001009. 
114. Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-
based medicine. Plast Reconstr Surg. 2011; 128(1):305-10. 
115. Allers K, Hoffmann F, Mathes T, Pieper D. Systematic reviews with published 
protocols compared to those without: more effort, older search. J Clin Epidemiol. 2018; 
95:102-10. 
116. Sideri S, Papageorgiou SN, Eliades T. Registration in the international prospective 
register of systematic reviews (PROSPERO) of systematic review protocols was 
associated with increased review quality. J Clin Epidemiol. 2018; 100:103-10. 
117. Dharmawardana N, Campbell JM, Carney AS, Boase S. Effectiveness of primary 
surgery versus primary radiotherapy on unknown primary head and neck squamous cell 




118. Brozek JL, Akl EA, Alonso-Coello P, Lang D, Jaeschke R, Williams JW, et al. 
Grading quality of evidence and strength of recommendations in clinical practice 
guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of 
evidence about interventions. Allergy. 2009; 64(5):669-77. 
119. The System for the Unified Management, Assessment and Review of Information 
(SUMARI). Joanna Briggs Institute; 2017 [cited 2018 Available from: 
https://www.jbisumari.org/ 
120. Kamal M, Mohamed ASR, Fuller CD, Sturgis EM, Johnson FM, Morrison WH, et 
al. Outcomes of patients diagnosed with carcinoma metastatic to the neck from an 
unknown primary source and treated with intensity-modulated radiation therapy. Cancer. 
2018; 124(7):1415-27. 
121. Collaboration TC. Review Manager (RevMan). Copenhagen: The Nordic Cochrane 
Centre; 2014. 
122. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions 
[updated March 2011]. . 2011 [cited 2019 Available from: www.handbook.cochrane.org 
123. Aromataris E, Munn Z. Joanna Briggs Institute Reviewer's Manual. Adelaide: Joanna 
Briggs Institute; 2017 [cited 2018 Available from: 
https://reviewersmanual.joannabriggs.org 
124. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for 
incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. 
125. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster 
University, Developed by Evidence Prime, Inc.; 2015 [cited 2019 Available from: 
http://www.gradepro.org 
126. Demiroz C, Vainshtein JM, Koukourakis GV, Gutfeld O, Prince ME, Bradford CR, 
et al. Head and neck squamous cell carcinoma of unknown primary: neck dissection and 
radiotherapy or definitive radiotherapy. Head Neck. 2014; 36(11):1589-95. 
127. Frank SJ, Rosenthal DI, Petsuksiri J, Ang KK, Morrison WH, Weber RS, et al. 
Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases 
from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and 
patterns of failure. Int J Radiat Oncol Biol Phys. 2010; 78(4):1005-10. 
128. Madani I, Vakaet L, Bonte K, Boterberg T, De Neve W. Intensity-modulated 
radiotherapy for cervical lymph node metastases from unknown primary cancer. Int J 
Radiat Oncol Biol Phys. 2008; 71(4):1158-66. 
129. Huo M, Panizza B, Bernard A, Porceddu SV. Head and neck squamous cell 
carcinoma of unknown primary: Outcomes of a pre-defined institutional treatment policy 
in a region with a high prevalence of skin cancer. Oral Oncol. 2018; 77:43-8. 
130. Mizuta M, Kitamura M, Tateya I, Tamaki H, Tanaka S, Asato R, et al. Unknown 
primary squamous cell carcinoma of the head and neck: retrospective analysis of 80 cases. 
Acta Otolaryngol. 2018; 138(6):590-6. 
73 
 
131. Chen AM, Meshman J, Hsu S, Yoshizaki T, Abemayor E, John MS. Oropharynx-
directed ipsilateral irradiation for p16-positive squamous cell carcinoma involving the 
cervical lymph nodes of unknown primary origin. Head Neck. 2018; 40(2):227-32. 
132. Watson M, Holman DM, Maguire-Eisen M. Ultraviolet Radiation Exposure and Its 
Impact on Skin Cancer Risk. Semin Oncol Nurs. 2016; 32(3):241-54. 
133. Al Kadah B, Papaspyrou G, Linxweiler M, Schick B, Rube C, Buchler BS, et al. 
Cancer of unknown primary (CUP) of the head and neck: retrospective analysis of 81 
patients. Eur Arch Otorhinolaryngol. 2017; 274(6):2557-66. 
134. National Comprehensive Cancer Network. Head and Neck Cancer (Version 2.2019). 
2019 [cited 2019 Available from: https://www.nccn.org/professionals/ 
135. Waltonen JD, Ozer E, Hall NC, Schuller DE, Agrawal A. Metastatic carcinoma of 
the neck of unknown primary origin: evolution and efficacy of the modern workup. Arch 
Otolaryngol Head Neck Surg. 2009; 135(10):1024-9. 
136. Zhuang SM, Wu XF, Li JJ, Zhang GH. Management of lymph node metastases from 
an unknown primary site to the head and neck (Review). Mol Clin Oncol. 2014; 2(6):917-
22. 
137. Boscolo-Rizzo P, Da Mosto MC, Gava A, Marchiori C. Cervical lymph node 
metastases from occult squamous cell carcinoma: analysis of 82 cases. ORL J 
Otorhinolaryngol Relat Spec. 2006; 68(4):189-94. 
138. Aslani M, Sultanem K, Voung T, Hier M, Niazi T, Shenouda G. Metastatic carcinoma 
to the cervical nodes from an unknown head and neck primary site: Is there a need for 
neck dissection? Head Neck. 2007; 29(6):585-90. 
139. Kale H, Rath TJ. Chapter 3 The Role of PET/CT in Squamous Cell Carcinoma of 
the Head and Neck. Semin Ultrasound CT MR. 2017; 38(5):479-94. 
140. Mackenzie K, Watson M, Jankowska P, Bhide S, Simo R. Investigation and 
management of the unknown primary with metastatic neck disease: United Kingdom 
National Multidisciplinary Guidelines. J Laryngol Otol. 2016; 130(S2):S170-S5. 
141. Winquist E, Agbassi C, Meyers BM, Yoo J, Chan KKW, Head, et al. Systemic 
therapy in the curative treatment of head-and-neck squamous cell cancer: Cancer Care 







Search strategy – PubMed 
(Carcinoma, squamous cell of head and neck[supplementary concept] OR 
Carcinoma, Squamous Cell[mh] OR human papillomavirus[tw] OR squamous cell 
carcinoma*[tw] OR squamous cell cancer*[tw] OR head and neck cancer*[tw] OR 
p16[tw] OR p-16[tw] OR unknown primary head and neck cancer[tw] OR head and neck 
cancer of unknown primary site[tw] OR head and neck carcinoma[tw] OR head and neck 
neoplasms[mh] OR unknown primary[tw] OR occult mucosal primary[tw] OR occult 
primary[tw]) AND (neck dissection[mh] OR tonsillectomy[tw] OR robotic surgical 
procedures[mh] OR lymph node excision[mh] OR surgery[tw] OR neck dissect*[tw] OR 
lymph node excisi*[tw] OR neck surgery[tw] OR surgical procedures, operative[mh]) 
AND (Radiotherapy[mh] OR radiotherapy, intensity-Modulated[mh] OR radiotherapy, 
conformal[mh] OR radiotherapy Dosage[mh] OR dose fractionation[mh] OR 
chemoradiotherapy[mh] OR chemoradiotherapy[tw] OR radiation therapy[tw] OR 
radiation oncology[tw] OR radiotherapy[tw] OR IMRT[tw] OR intensity modulated 
radiotherapy[tw]) 
Search strategy – Embase 
(('head and neck squamous cell carcinoma':de,ti,ab OR 'squamous cell 
carcinoma':de,ti,ab OR 'wart virus':de OR 'squamous cell carcinoma*' OR 'squamous cell 
cancer*' OR 'head and neck cancer*' OR 'p16' OR 'p-16' OR 'cancer of unknown primary 
site':de,ti,ab OR 'head and neck cancer of unknown primary site' OR 'head and neck 
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carcinoma':de,ti,ab OR 'head and neck tumor':de,ti,ab OR 'head and neck squamous cell 
carcinoma'/exp OR 'head and neck squamous cell carcinoma' OR 'squamous cell 
carcinoma'/exp OR 'squamous cell carcinoma' OR 'head and neck carcinoma'/exp OR 
'head and neck carcinoma' OR 'head and neck tumor'/exp OR 'head and neck tumor' OR 
'cancer of unknown primary site'/exp OR 'cancer of unknown primary site') AND 
('unknown primary'/exp OR 'unknown primary')) AND ('neck dissection':de,ti,ab OR 
'tonsillectomy':de,ti,ab OR 'robotic surgical procedure':de,ti,ab OR 'lymph node 
dissection':de,ti,ab OR 'surgery':de,ti,ab OR 'neck dissect*' OR 'lymph node excisi*' OR 
'neck surgery' OR 'neck dissection' OR 'tonsillectomy' OR 'robotic surgical procedure' OR 
'lymph node dissection' OR 'surgery') AND ('radiotherapy':de,ti,ab OR 'radiotherapy, 
intensity-modulated':de,ti,ab OR 'conformal radiotherapy':de,ti,ab OR 'radiation dose 
escalation':de,ti,ab OR 'radiation dose fractionation':de,ti,ab OR 
'chemoradiotherapy':de,ti,ab OR 'adjuvant chemoradiotherapy':de,ti,ab OR 'radiation 
therapy' OR 'radiation oncology' OR 'radiotherapy' OR 'imrt' OR 'intensity modulated 
radiotherapy' OR 'radiation dose' OR 'chemotherapy':de,ti,ab OR 'chemotherapy') 
Search strategy – ProQuest Theses and Dissertations 
AB(Carcinoma, squamous cell of head and neck OR Carcinoma, Squamous Cell 
OR human papillomavirus OR squamous cell carcinoma* OR squamous cell cancer* OR 
head and neck cancer* OR p16 OR p-16 OR unknown primary head and neck cancer OR 
head and neck cancer of unknown primary site OR head and neck carcinoma OR head 
and neck neoplasms OR unknown primary OR occult mucosal primary OR occult 
primary) AND AB(neck dissection OR tonsillectomy OR robotic surgical procedures OR 
lymph node excision OR surgery OR neck dissect* OR lymph node excisi* OR neck 
surgery OR surgical procedures, operative) AND AB(Radiotherapy OR radiotherapy, 
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intensity-Modulated OR radiotherapy, conformal OR radiotherapy Dosage OR dose 
fractionation OR chemoradiotherapy OR chemoradiotherapy OR radiation therapy OR 
radiation oncology OR radiotherapy OR IMRT OR intensity modulated radiotherapy) 
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JBI Critical Appraisal Checklist for Cohort Studies 
Reviewer     Date      
Author      Year  Record Number   
 
 Yes No Unclear Not 
applicable 
1. Were the two groups similar and recruited from 
the same population? 
□ □ □ □ 
2. Were the exposures measured similarly to assign 
people  
to both exposed and unexposed groups? 
□ □ □ □ 
3. Was the exposure measured in a valid and 
reliable way? 
□ □ □ □ 
4. Were confounding factors identified? 
□ □ □ □ 
5. Were strategies to deal with confounding factors 
stated? 
□ □ □ □ 
6. Were the groups/participants free of the outcome 
at the start of the study (or at the moment of 
exposure)? 
□ □ □ □ 
7. Were the outcomes measured in a valid and 
reliable way? 
□ □ □ □ 
8. Was the follow up time reported and sufficient to 
be long enough for outcomes to occur? 
□ □ □ □ 
9. Was follow up complete, and if not, were the 
reasons to loss to follow up described and 
explored? 
□ □ □ □ 
10. Were strategies to address incomplete follow up 
utilized? 
□ □ □ □ 
11. Was appropriate statistical analysis used? 
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Estimation of survival data from Kaplan-Meier plot 
As mentioned in Section 2.9 of this thesis, studies included in this review did not 
report comparable time to event data intervals.  Therefore, Kaplan-Meier estimate curves 
were used to manually estimate survival rates for each time interval.  As illustrated in 
Figure A-1, lines were drawn manually at each time interval and the corresponding 
survival rate was documented at the intercept point.  These values were then entered into 
the worksheet provided by Tierney et a.l116 to complete the calculation of hazard ratios.  
When patient ‘number at risk’ (highlighted in yellow in Figure A-1) were provided in the 
Kaplan-Meier plots, this data was included to also allow for more accurate calculation of 
summary statistics; ‘number at risk’ values indicate patients lost to follow-up, a value 
difficult to ascertain from isolated plots.  The survival values estimated here were also 
used for correlation and regression analysis for the two-year overall survival mark (see 
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Section 2.9).  The two-year survival rates were chosen as these represented the minimum 
from those reported across two-, three-, four- or five-year intervals from the included 
studies. 
 
Figure A - 1. Example of a manual drawing of ‘green’ lines to estimate overall survival for each 
time interval.  This graph was modified from Huo et al.129 
 
Calculation of hazard ratios 
The list of figures below (Figures A-2 to A-9) record the HR calculations based on 
a worksheet provided by Tierney et al.124  Calculations for each study was based on the 
data available and each figure below indicates which set of data was used to calculated 












Figure A - 4. Worksheet for overall survival summary statistic calculation for Huo et al.129 
 
 









Figure A - 7. Worksheet for regional relapse free survival summary statistic calculation for 






Figure A - 8. Worksheet for regional relapse free survival summary statistic calculation for 
Demiroz et al.126 
 
 
Figure A - 9. Worksheet for regional relapse free survival summary statistic calculation for 
Mizuta et al.130 
